---
title: "Inaxaplin (VX-147) in APOL1-mediated kidney disease: Clinical evidence"
description: "Formulary evidence on Inaxaplin (VX-147) in APOL1-mediated kidney disease: Clinical evidence. Covers AMPLITUDE, VX19-147-101, AMPLIFIED, VX18-147-001, VX20-147-008, VX19-147-007, and 2 further headings. 323 evidence topics quoted from 46 sources."
canonical: "https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/clinical-evidence"
published: "2026-11-15T23:17:22-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Inaxaplin (VX-147) in APOL1-mediated kidney disease: Clinical evidence

<a id="clinical-evidence"></a>

## 3 Clinical Evidence

<a id="heading-3.1"></a>

### 3.1 Study Summaries

<a id="heading-3.1.1"></a>

#### 3.1.1 AMPLITUDE

<a id="heading-3.1.1.1"></a>

##### 3.1.1.1 Objective

<a id="topic-3.1.1.1-1"></a>

###### Purpose stated in the ClinicalTrials.gov brief summary

> “The purpose of this study is to evaluate the efficacy, safety, tolerability, and pharmacokinetics (PK) of VX-147 in adult and pediatric participants with apolipoprotein L1 (APOL1)-mediated proteinuric kidney disease.”

Source: [ClinicalTrials.gov NCT05312879](https://clinicaltrials.gov/study/NCT05312879)

<a id="topic-3.1.1.1-2"></a>

###### Main objective in the EU Clinical Trials Information System record

> “Main objective Evaluate efficacy and safety of VX-147 in subjects with AMKD”

Source: [EU Clinical Trials Information System 2024-515633-15-00](https://euclinicaltrials.eu/ctis-public/view/2024-515633-15-00)

<a id="topic-3.1.1.1-3"></a>

###### Scope and secondary objectives of Part A and Part B in the EU register record

> “Scope: Efficacy, Safety, Pharmacokinetic”
> “To evaluate the safety and tolerability of VX-147”
> “To identify the optimal dose from Phase 2 to carry forward to Phase 3”
> “To characterize the plasma pharmacokinetics (PK) of VX-147”
> “To evaluate the acceptability of VX-147 in pediatric subjects”
> “Part B: To evaluate changes in proteinuria and kidney function after long-term VX-147 treatment in adult and pediatric subjects”

Source: [CTIS.eu 2024-515633-15-00](https://ctis.eu/trial/2024-515633-15-00)

<a id="topic-3.1.1.1-4"></a>

###### Aim of the trial stated by the company

> “AMPLITUDE is a global Phase 2/3 clinical trial designed to assess the impact of inaxaplin on kidney function and proteinuria for people living with AMKD.”

Source: [Vertex Pharmaceuticals press release, AMPLIFIED results (2026)](https://news.vrtx.com/news-releases/news-release-details/vertex-announces-positive-results-phase-2b-amplified-study)

<a id="topic-3.1.1.1-5"></a>

###### Aim of the trial stated in the design abstract

> “This Ph2/3 adaptive trial will determine the efficacy and safety of IXP in preserving kidney function and reducing proteinuria in a broad population with AMKD.”

Source: [Falk et al. (2022)](https://www.ovid.com/jnls/jasn/fulltext/10.1681/asn.20223311s1181c~design-of-a-phase-23-adaptive-trial-evaluating-inaxaplin-in)

<a id="heading-3.1.1.2"></a>

##### 3.1.1.2 Location and Study Date

<a id="topic-3.1.1.2-1"></a>

###### Study dates and status in the ClinicalTrials.gov record

> “Study Start (Actual) 2022-03-30”
> “Primary Completion (Estimated) 2028-06-02”
> “Study Completion (Estimated) 2030-05-07”
> “First Posted 2022-04-06”
> “Last Update Posted 2026-10-26”
> “Active, not recruiting”

Source: [ClinicalTrials.gov NCT05312879](https://clinicaltrials.gov/study/NCT05312879)

<a id="topic-3.1.1.2-2"></a>

###### Number of locations in the ClinicalTrials.gov record

> “This study has 314 locations”

Source: [ClinicalTrials.gov NCT05312879](https://clinicaltrials.gov/study/NCT05312879)

<a id="topic-3.1.1.2-3"></a>

###### Study locations by country in the ClinicalTrials.gov record

| Country | Locations listed in the record |
| --- | --- |
| United States | “Alabama Locations”; “Arizona Locations”; “Arkansas Locations”; “California Locations”; “Connecticut Locations”; “District of Columbia Locations”; “Florida Locations”; “Georgia Locations”; “Illinois Locations”; “Indiana Locations”; “Iowa Locations”; “Kansas Locations”; “Louisiana Locations”; “Maryland Locations”; “Massachusetts Locations”; “Michigan Locations”; “Minnesota Locations”; “Mississippi Locations”; “Missouri Locations”; “Nevada Locations”; “New Jersey Locations”; “New Mexico Locations”; “New York Locations”; “North Carolina Locations”; “Ohio Locations”; “Pennsylvania Locations”; “Rhode Island Locations”; “South Carolina Locations”; “Tennessee Locations”; “Texas Locations”; “Virginia Locations”; “Washington Locations”; “Wisconsin Locations” |
| Belgium | “Brussels, Belgium”; “Leuven, Belgium” |
| Brazil | “Aracaju, Brazil”; “Belo Horizonte, Brazil”; “Botucatu, Brazil”; “Campinas, Brazil”; “Curitiba, Brazil”; “Fortaleza, Brazil”; “Goiânia, Brazil”; “Juiz de Fora, Brazil”; “Marília, Brazil”; “Monte Alegre, Brazil”; “Porto Alegre, Brazil”; “Recife, Brazil”; “Rio de Janeiro, Brazil”; “Salvador, Brazil”; “Santo André, Brazil”; “São José do Rio Preto, Brazil”; “São Paulo, Brazil” |
| Canada | “Montreal, Canada”; “Toronto, Canada” |
| Colombia | “Atlántico, Colombia”; “Bogotá, Colombia”; “Cali, Colombia”; “Cartagena, Colombia”; “Ibague, Colombia”; “Medellín, Colombia” |
| France | “Créteil, France”; “Grenoble, France”; “Le Kremlin-Bicêtre, France”; “Limoges, France”; “Marseille, France”; “Paris, France”; “Pointe à Pitre, France”; “Saint-Ouen, France”; “Toulouse, France” |
| Ghana | “Accra, Ghana”; “Cantonments, Ghana”; “Kumasi, Ghana” |
| Netherlands | “Amsterdam, Netherlands” |
| Nigeria | “Enugu, Nigeria”; “Ibadan, Nigeria”; “Idi-Araba, Nigeria”; “Ikeja, Nigeria”; “Lagos, Nigeria” |
| Portugal | “Amadora, Portugal”; “Lisbon, Portugal”; “Loures, Portugal” |
| Puerto Rico | “Mayagüez, Puerto Rico, 06680”; “Rio Piedras, Puerto Rico, 00935”; “San Juan, Puerto Rico, 00917” |
| Spain | “Barcelona, Spain”; “Córdoba, Spain”; “Madrid, Spain”; “Seville, Spain” |
| United Kingdom | “Basildon, United Kingdom”; “Bellshill, United Kingdom”; “Birmingham, United Kingdom”; “Carshalton, United Kingdom”; “Leicester, United Kingdom”; “London, United Kingdom”; “Manchester, United Kingdom”; “Nottingham, United Kingdom” |

Source: [ClinicalTrials.gov NCT05312879](https://clinicaltrials.gov/study/NCT05312879)

<a id="topic-3.1.1.2-4"></a>

###### EU member states, trial start, and estimated end of trial in the EU Clinical Trials Information System record

> “Locations Belgium, France”
> “Start of trial 25/10/2022”
> “Estimated recruitment start date in EU/EEA: 29/03/2022”
> “Estimated end of trial date in EU/EEA: 31/05/2028”
> “Estimated global end date of the trial: 31/05/2028”

Source: [EU Clinical Trials Information System 2024-515633-15-00](https://euclinicaltrials.eu/ctis-public/view/2024-515633-15-00)

<a id="topic-3.1.1.2-5"></a>

###### Recruitment end in the EU member states

> “Belgium: Ongoing, recruitment ended. Planned participants: 2”
> “France: Ongoing, recruitment ended. Planned participants: 40”
> “15 Sept 2026 Recruitment ended Belgium, France”

Source: [CTIS.eu 2024-515633-15-00](https://ctis.eu/trial/2024-515633-15-00)

<a id="topic-3.1.1.2-6"></a>

###### First authorization and status by country in the earlier EU Clinical Trials Register record

> “First authorisation by a national competent authority 7 Jun 2022”
> “Transitioned to the EU register: Belgium”
> “Ongoing: Spain”
> “Completed: Netherlands”
> “Prematurely ended: Portugal”

Source: [CTIS.eu 2024-515633-15-00](https://ctis.eu/trial/2024-515633-15-00)

<a id="topic-3.1.1.2-7"></a>

###### Trial start year stated by the company

> “We initiated pivotal development of inaxaplin in a single Phase 2/3 adaptive clinical trial”
> “in people with AMKD in 2022.”

Source: [Vertex Pharmaceuticals Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/875320/000087532026000056/vrtx-20251231.htm)

<a id="topic-3.1.1.2-8"></a>

###### Number of open sites stated by the company in 2023 and 2024

> “Enrollment in the study is ongoing, with more than 100 sites open in the U.S. and internationally, with 250 planned sites in total globally.”

Source: [Vertex Pharmaceuticals press release, NEJM publication (2023)](https://news.vrtx.com/news-releases/news-release-details/vertex-announces-publication-new-england-journal-medicine)

> “Enrollment in the study is ongoing, with more than 200 sites open in the U.S. and internationally.”

Source: [Vertex Pharmaceuticals press release, phase 3 advancement (2024)](https://news.vrtx.com/news-releases/news-release-details/vertex-advances-inaxaplin-vx-147-phase-3-portion-adaptive-phase)

<a id="topic-3.1.1.2-9"></a>

###### Countries in the phase 3 portion stated in the design abstract

> “Phase 3 is ongoing in nine countries, including Belgium and France in Europe.”

Source: [Chertow et al. (2025a)](https://doi.org/10.1093/ndt/gfaf116.0477)

<a id="heading-3.1.1.3"></a>

##### 3.1.1.3 Study Design

<a id="topic-3.1.1.3-1"></a>

###### Official title in the ClinicalTrials.gov record

> “A Phase 2/3 Adaptive, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of VX-147 in Adult and Pediatric Subjects With APOL1-mediated Proteinuric Kidney Disease”

Source: [ClinicalTrials.gov NCT05312879](https://clinicaltrials.gov/study/NCT05312879)

<a id="topic-3.1.1.3-2"></a>

###### Design details in the ClinicalTrials.gov record

> “Primary Purpose : Treatment”
> “Allocation : Randomized”
> “Interventional Model : Sequential Assignment”
> “Masking : Quadruple”

Source: [ClinicalTrials.gov NCT05312879](https://clinicaltrials.gov/study/NCT05312879)

<a id="topic-3.1.1.3-3"></a>

###### Integrated phase 2 and phase 3 trial in the EU Clinical Trials Information System record

> “Trial Phase Phase II and Phase III (Integrated)”
> “Transition trial Yes”

Source: [EU Clinical Trials Information System 2024-515633-15-00](https://euclinicaltrials.eu/ctis-public/view/2024-515633-15-00)

<a id="topic-3.1.1.3-4"></a>

###### Single pivotal adaptive trial with a phase 2 dose-selection portion

> “The company will evaluate the safety and efficacy of VX-147 in a single pivotal clinical trial designed to assess the impact of VX-147, on top of standard of care, on kidney function and proteinuria in people with AMKD.”
> “This randomized, double-blind, placebo-controlled Phase 2/3 adaptive study will first evaluate two doses of VX-147 for 12 weeks to select a dose for Phase 3 and subsequently evaluate the efficacy and safety of the single, selected dose in the Phase 3 portion of the study.”

Source: [Vertex Pharmaceuticals press release, pivotal development (2022)](https://news.vrtx.com/news-releases/news-release-details/vertex-advances-vx-147-pivotal-clinical-development-people-apol1)

<a id="topic-3.1.1.3-5"></a>

###### Phase 2 portion: two doses or placebo for 12 weeks

> “participants will be randomized to receive 1 of 2 daily doses of IXP or placebo for 12wks.”

Source: [Falk et al. (2022)](https://www.ovid.com/jnls/jasn/fulltext/10.1681/asn.20223311s1181c~design-of-a-phase-23-adaptive-trial-evaluating-inaxaplin-in)

<a id="topic-3.1.1.3-6"></a>

###### Dose selection for phase 3 by the independent data monitoring committee

> “An Independent Data Monitoring Committee (IDMC) reviewed blinded and unblinded Phase 2 safety and efficacy data from the Phase 2/3 pivotal trial, which evaluated two different doses of inaxaplin compared to placebo for 12 weeks of treatment in patients ages 18 to 65 years and recommended the selection of a single inaxaplin dose of 45 mg once daily in the Phase 3 portion of the Phase 2/3 study.”

Source: [Vertex Pharmaceuticals press release, phase 3 advancement (2024)](https://news.vrtx.com/news-releases/news-release-details/vertex-advances-inaxaplin-vx-147-phase-3-portion-adaptive-phase)

> “In the AMPLITUDE trial, we selected a 45 mg inaxaplin once daily dose for Phase 3 after the Phase 2 efficacy/safety data had been reviewed by an independent data monitoring committee.”

Source: [Chertow et al. (2025a)](https://doi.org/10.1093/ndt/gfaf116.0477)

<a id="topic-3.1.1.3-7"></a>

###### Pediatric cohort: adolescents aged 10 to 17 years added to the phase 3 portion

> “In addition, the trial has been expanded to include adolescents with AMKD ages 10 to 17 years.”
> “The IDMC also recommended enrolling adolescents with AMKD ages 10 to 17 years in the Phase 3 portion of the study.”

Source: [Vertex Pharmaceuticals press release, phase 3 advancement (2024)](https://news.vrtx.com/news-releases/news-release-details/vertex-advances-inaxaplin-vx-147-phase-3-portion-adaptive-phase)

<a id="topic-3.1.1.3-8"></a>

###### Pre-planned interim analysis at week 48 in a pre-specified number of participants

> “The AMPLITUDE study is designed with an interim analysis at Week 48 in a pre-specified number of patients to assess percent change from baseline in proteinuria and eGFR slope in the inaxaplin arm versus placebo.”

Source: [Vertex Pharmaceuticals press release, kidney portfolio advancements (2025)](https://news.vrtx.com/news-releases/news-release-details/vertex-announces-key-advancements-across-kidney-portfolio)

<a id="topic-3.1.1.3-9"></a>

###### Part B open-label extension: 96 additional weeks of inaxaplin

> “Experimental: Part B (Phase 3): VX-147”
> “Participants who complete Part A will receive VX-147 for an additional 96 weeks.”

Source: [ClinicalTrials.gov NCT05312879](https://clinicaltrials.gov/study/NCT05312879)

<a id="topic-3.1.1.3-10"></a>

###### Final analysis triggered by follow-up duration and number of composite outcomes

> “The final study analysis will occur when subjects have at least two years of eGFR data and when approximately 187 composite clinical outcomes have occurred.”

Source: [Vertex Pharmaceuticals press release, kidney portfolio advancements (2025)](https://news.vrtx.com/news-releases/news-release-details/vertex-announces-key-advancements-across-kidney-portfolio)

<a id="topic-3.1.1.3-11"></a>

###### Independent data monitoring committee in the ClinicalTrials.gov data summarized by the EU register mirror

> “Drug regulated by the U.S. FDA; Data monitoring committee”

Source: [CTIS.eu 2024-515633-15-00](https://ctis.eu/trial/2024-515633-15-00)

Additional sources: [Chertow et al. (2024)](https://www.ovid.com/jnls/jasn/fulltext/10.1681/asn.20241x7qn0bv~amplitude-a-phase-23-adaptive-trial-of-inaxaplin-in)

<a id="heading-3.1.1.4"></a>

##### 3.1.1.4 Eligibility Criteria

<a id="topic-3.1.1.4-1"></a>

###### Key inclusion and exclusion criteria in the ClinicalTrials.gov record

> “APOL1 genotype of G1/G1, G2/G2, or G1/G2”
> “Proteinuric kidney disease”
> “Completion of Treatment Period in Part A and no permanent discontinuation of study drug.”
> “Solid organ or bone marrow transplant”
> “Uncontrolled hypertension”
> “History of diabetes mellitus”
> “Known underlying cause of kidney disease including but not limited to sickle cell disease”
> “ESKD (End Stage Kidney Disease) as defined in the protocol.”
> “Any lab abnormality that may pose a safety risk to the participant, as judged by the investigator.”

Source: [ClinicalTrials.gov NCT05312879](https://clinicaltrials.gov/study/NCT05312879)

<a id="topic-3.1.1.4-2"></a>

###### Ages and sexes eligible in the ClinicalTrials.gov record

> “10 Years to 65 Years”
> “Sexes Eligible for Study All”
> “Accepts Healthy Volunteers No”

Source: [ClinicalTrials.gov NCT05312879](https://clinicaltrials.gov/study/NCT05312879)

<a id="topic-3.1.1.4-3"></a>

###### Part A inclusion criteria: genotype, age, body size, proteinuria, and kidney function in the EU register record

> “Subject has an APOL1 genotype of G1/G1, G2/G2, or G1/G2 obtained with a Vertex designated investigational clinical study assay.”
> “For Phase 2, subjects must be between the ages of 18 and 65 years at time of signing first ICF, inclusive. For Phase 3, subjects must be between the ages of 12 and 65 years at time of signing first ICF, inclusive.”
> “Pediatric subjects may be enrolled only after IDMC review of Phase 2 data is completed, the Phase 3 dose is selected, and a recommendation by the IDMC on the inclusion of pediatric subjects is made.”
> “Up to approximately 15% of the total number of subjects planned for enrollment may be >61 to ≤65 years of age at time of signing first ICF, inclusive.”
> “A BMI of 18 to 45 kg/m2, inclusive, and a total body weight ≥40 kg.”
> “A UPCR of ≥0.7 g/g to <10 g/g in the first morning void based on the average of 3 measurements collected on 3 separate days within a 7-day period, during the Screening Period.”
> “Estimated glomerular filtration rate (eGFR) ≥25 to < 75 mL/min/1.73 m2 during the Screening Period”

Source: [CTIS.eu 2024-515633-15-00](https://ctis.eu/trial/2024-515633-15-00)

<a id="topic-3.1.1.4-4"></a>

###### Part A inclusion criteria: stable background therapy in the EU register record

> “On a stable, maximum tolerated labeled dose (at least 4 weeks before screening) of an angiotensin converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB), but not both concomitantly, unless documented to be intolerant to ACE inhibitor/ARB.”
> “Subjects taking sodium glucose co transporter 2 (SGLT2) inhibitors, glucagon-like peptide-1 receptor agonist (GLP 1a), mineralocorticoid receptor antagonists (MRAs), endothelin antagonists, sparsentan, or permitted immunosuppressants (prednisone ≤10 mg or steroid equivalent, mycophenolate, tacrolimus, cyclosporine, or azathioprine) must have been on a stable dose for 4 weeks before screening.”

Source: [CTIS.eu 2024-515633-15-00](https://ctis.eu/trial/2024-515633-15-00)

<a id="topic-3.1.1.4-5"></a>

###### Part A exclusion criteria in the EU register record

> “Evidence of FSGS with a known cause other than due to APOL1 mutations.”
> “History of diabetes mellitus. A diagnosis of prediabetes is permitted.”
> “Known underlying cause of kidney disease”
> “Risk factors for Torsade de Pointes (e.g., familial long QT syndrome, chronic hypokalemia, heart failure) or concomitant medications that prolong the QT/QTc interval or any history of cardiac disorders”
> “Positive for hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) RNA, or positive HIV test”
> “Screening blood pressure, based on the average of 3 measurements, of ≥180 mm Hg (systolic) or ≥100 mm Hg (diastolic).”
> “Pregnant or nursing female subjects.”

Source: [CTIS.eu 2024-515633-15-00](https://ctis.eu/trial/2024-515633-15-00)

<a id="topic-3.1.1.4-6"></a>

###### Part B inclusion and exclusion criteria in the EU register record

> “Subject did not withdraw consent during Part A of the study.”
> “ESKD as defined in Section 9.10.1, in Part A.”
> “Ongoing or planned participation in another interventional, therapeutic clinical trial other than Part A of the study.”

Source: [CTIS.eu 2024-515633-15-00](https://ctis.eu/trial/2024-515633-15-00)

<a id="topic-3.1.1.4-7"></a>

###### Eligibility summarized in the 2025 design abstract

> “Our Phase 2/3, randomized, double-blind, placebo-controlled, adaptive trial is enrolling persons without diabetes (Phase 2: 18 to 65 years; Phase 3: 10 to 65 years) with 2 APOL1 variants, UPCR ≥0.7 to <10 g/g, and eGFR ≥25 to <75 mL/min/1.73 m2.”

Source: [Chertow et al. (2025a)](https://doi.org/10.1093/ndt/gfaf116.0477)

<a id="topic-3.1.1.4-8"></a>

###### Original eligibility at trial start: ages 18 to 60 years

> “Patients aged 18 to 60 years, with two APOL1 mutations, urine protein to creatinine ratio (UPCR) ≥0.7 g/g to <10 g/g, eGFR ≥25 to <75 mL/min/1.73m2 and on stable doses of standard of care medications are eligible to enroll.”

Source: [Vertex Pharmaceuticals press release, pivotal development (2022)](https://news.vrtx.com/news-releases/news-release-details/vertex-advances-vx-147-pivotal-clinical-development-people-apol1)

<a id="topic-3.1.1.4-9"></a>

###### Population described by the company: severe proteinuria and no comorbidities causing kidney disease

> “Vertex has completed full enrollment in the Phase 2/3 AMPLITUDE study of inaxaplin in people with severe proteinuria and no other kidney disease-causing comorbidities.”

Source: [Vertex Pharmaceuticals press release, AMPLIFIED results (2026)](https://news.vrtx.com/news-releases/news-release-details/vertex-announces-positive-results-phase-2b-amplified-study)

> “The phase 2/3 randomized, placebo-controlled AMPLITUDE trial is evaluating the effects of IXP on preserving kidney function and reducing proteinuria in non-diabetic persons with AMKD and severe proteinuria (UPCR ≥0.7 to <10g/g).”

Source: [Chertow et al. (2025b)](https://www.ovid.com/jnls/jasn/fulltext/10.1681/asn.20252q319dky~inaxaplin-for-a-broad-population-with-apol1-mediated-kidney)

<a id="heading-3.1.1.5"></a>

##### 3.1.1.5 Treatment

<a id="topic-3.1.1.5-1"></a>

###### Arms and interventions in the ClinicalTrials.gov record

| Arm | Description | Intervention |
| --- | --- | --- |
| Part A, inaxaplin | “Experimental: Part A (Phase 2/3): VX-147”; “Participants will be randomized to receive different doses of VX-147. Participants will receive the selected dose of VX-147 for atleast 96 weeks.” | “Drug: VX-147”; “Tablets for oral administration.” |
| Part A, placebo | “Placebo Comparator: Part A (Phase 2/3): Placebo”; “Participants will receive placebo matched to VX-147.” | “Drug: Placebo”; “Tablets for oral administration.” |
| Part B, inaxaplin | “Experimental: Part B (Phase 3): VX-147”; “Participants who complete Part A will receive VX-147 for an additional 96 weeks.” | “Drug: VX-147”; “Tablets for oral administration.” |

Source: [ClinicalTrials.gov NCT05312879](https://clinicaltrials.gov/study/NCT05312879)

<a id="topic-3.1.1.5-2"></a>

###### Phase 3 dose: inaxaplin 45 mg once daily or placebo added to standard of care

> “Inaxaplin is being evaluated as a 45 mg once-daily oral dose compared to placebo, on top of standard of care.”

Source: [Vertex Pharmaceuticals press release, AMPLIFIED results (2026)](https://news.vrtx.com/news-releases/news-release-details/vertex-announces-positive-results-phase-2b-amplified-study)

<a id="topic-3.1.1.5-3"></a>

###### Investigational medicinal product and placebo in the EU register record

| Field | Quoted record |
| --- | --- |
| Test product | “VX-147 film-coated tablet” |
| Maximum daily dose | “45 mg milligram(s)” |
| Maximum total dose | “4860 mg milligram(s)” |
| Maximum duration of treatment | “108 week(s)” |
| Orphan designation number | “EMA/OD/0000090156” |
| Placebo | “VX-147, Coated Placebo Tablet” |

Source: [CTIS.eu 2024-515633-15-00](https://ctis.eu/trial/2024-515633-15-00)

<a id="topic-3.1.1.5-4"></a>

###### Phase 2 portion: two inaxaplin doses or placebo for 12 weeks

> “In the Phase 2 component, participants received inaxaplin (different doses) or placebo for 12 weeks to select a dose for evaluation of inaxaplin efficacy/safety in ∼400 participants in Phase 3.”

Source: [Chertow et al. (2025a)](https://doi.org/10.1093/ndt/gfaf116.0477)

<a id="heading-3.1.1.6"></a>

##### 3.1.1.6 Study Outcomes

<a id="heading-3.1.1.6.1"></a>

###### 3.1.1.6.1 Rationale for Using Percent Change in UPCR at Week 48 and eGFR Slope as the Primary Endpoints

<a id="topic-3.1.1.6.1-1"></a>

###### Registered primary outcome measures in the ClinicalTrials.gov record

| Outcome measure | Time frame |
| --- | --- |
| “Part A: Percent Change From Baseline in Urine Protein to Creatinine Ratio (UPCR) at Week 48 (Assessed at the Week 48 Interim Analysis)” | “From Baseline to Week 48” |
| “Part A: Estimated Glomerular Filtration Rate (eGFR) Slope Assessed at Interim Analysis” | “From Baseline Through >= Week 48” |
| “Part A: eGFR Slope Assessed at Final Analysis” | “From Baseline Through Study Completion (At least 2 years of eGFR data assessed at the final analysis)” |
| “Part B: Safety and Tolerability as Assessed by Number of Participants With Adverse events (AEs) and Serious Adverse Events (SAEs)” | “Day 1 Through Study Completion (Approximately 4 Years After the Last Participant Enrolls)” |

Source: [ClinicalTrials.gov NCT05312879](https://clinicaltrials.gov/study/NCT05312879)

<a id="topic-3.1.1.6.1-2"></a>

###### Registered secondary outcome measures in the ClinicalTrials.gov record

| Outcome measure | Time frame |
| --- | --- |
| “Part A: Safety and Tolerability as Assessed by Number of Participants With Adverse events (AEs) and Serious Adverse Events (SAEs)” | “Day 1 Through Study Completion (Approximately 2 Years After the Last Participant Enrolls)” |
| “Part A: Maximum Plasma Concentration (Cmax) of VX-147” | “Day 1 and Week 40” |
| “Part A: Area Under the Concentration Versus Time Curve During a Dosing Interval (AUCtau) of VX-147” | “Day 1 and Week 40” |
| “Part A: Observed Pre-dose Plasma Concentration (Ctrough) of VX-147” | “Day 1 up to Week 40” |
| “Part A: Acceptability Tablet Formulation of VX-147 in Pediatric Participants using the Convenience Domain of the Treatment Satisfaction Questionnaire for Medication (TSQM) Version 1.4” | “Day 1 and Week 48” |
| “Part B: Percent Change From Baseline in UPCR Over Time” | “From Baseline Through Study Completion (Approximately 4 Years After the Last Participant Enrolls)” |
| “Part B: eGFR Slope Assessment” | “Day 1 Through Study Completion (Approximately 4 Years After the Last Participant Enrolls)” |

Source: [ClinicalTrials.gov NCT05312879](https://clinicaltrials.gov/study/NCT05312879)

<a id="topic-3.1.1.6.1-3"></a>

###### Primary and secondary end points in the EU register record

> “Part A: Percent change in UPCR evaluated from baseline at Week 48 (assessed at the IA)”
> “eGFR slope (with ≥48 weeks of eGFR data assessed at the IA and at least 2 years of eGFR data assessed at the final analysis)”
> “Part B: Safety and tolerability assessments based on AEs, clinical laboratory values, and vital signs”
> “Part A: Acceptability of tablet formulation of VX-147 in pediatric subjects using the convenience domain of the Treatment Satisfaction Questionnaire for Medication (TSQM)”
> “Part B: Percent change in UPCR from baseline over time”

Source: [CTIS.eu 2024-515633-15-00](https://ctis.eu/trial/2024-515633-15-00)

<a id="topic-3.1.1.6.1-4"></a>

###### Final analysis: eGFR slope primary endpoint and composite clinical outcome secondary endpoint

> “The primary efficacy endpoint for the final analysis is eGFR slope in patients receiving the inaxaplin selected dose compared to placebo. The secondary efficacy endpoint is time to composite clinical outcome, which will also be assessed at the final analysis and is defined as a sustained decline of ≥30% from baseline in eGFR, the onset of end-stage kidney disease (i.e., maintenance dialysis for ≥28 days, kidney transplantation, or a sustained eGFR of <15 mL/min/1.73 m2), or death.”

Source: [Vertex Pharmaceuticals press release, Breakthrough Therapy and PRIME designations (2022)](https://news.vrtx.com/news-releases/news-release-details/vertex-announces-inaxaplin-vx-147-granted-breakthrough-therapy)

<a id="topic-3.1.1.6.1-5"></a>

###### Interim analysis endpoints as first described: eGFR slope supported by proteinuria

> “The study is also designed to have a pre-planned interim analysis at Week 48 evaluating eGFR slope in VX-147 versus placebo, supported by a percent change from baseline in proteinuria. If positive, the interim analysis may serve as the basis for Vertex to seek accelerated approval of VX-147 in the U.S. for patients with AMKD.”

Source: [Vertex Pharmaceuticals press release, pivotal development (2022)](https://news.vrtx.com/news-releases/news-release-details/vertex-advances-vx-147-pivotal-clinical-development-people-apol1)

<a id="topic-3.1.1.6.1-6"></a>

###### Interim analysis endpoints in the design abstract: UPCR and eGFR slope

> “The trial has a pre-planned interim analysis at Week 48 evaluating proteinuria, as measured by the percent change from baseline in UPCR, and eGFR slope.”

Source: [Falk et al. (2022)](https://www.ovid.com/jnls/jasn/fulltext/10.1681/asn.20223311s1181c~design-of-a-phase-23-adaptive-trial-evaluating-inaxaplin-in)

<a id="topic-3.1.1.6.1-7"></a>

###### Discussions with the FDA on the accelerated approval pathway

> “We are very pleased to have concluded our discussions with the FDA, enabling us to initiate the pivotal development program evaluating VX-147 in the broad patient population with AMKD and to have a clear path forward for potential accelerated approval in the U.S.”
> “The primary endpoint of this study is reduction in the rate of decline of kidney function as measured by estimated glomerular filtration rate (eGFR) slope versus placebo at approximately two years.”

Source: [Vertex Pharmaceuticals press release, pivotal development (2022)](https://news.vrtx.com/news-releases/news-release-details/vertex-advances-vx-147-pivotal-clinical-development-people-apol1)

<a id="topic-3.1.1.6.1-8"></a>

###### Interim analysis as the basis for an accelerated approval application

> “If positive, the IA will serve as the basis for Vertex to seek accelerated approval of inaxaplin in the U.S.”

Source: [Vertex Pharmaceuticals press release, kidney portfolio advancements (2025)](https://news.vrtx.com/news-releases/news-release-details/vertex-announces-key-advancements-across-kidney-portfolio)

<a id="topic-3.1.1.6.1-9"></a>

###### GFR slope as a surrogate endpoint: individual participant data meta-analysis of 66 studies

> “Treatment effects on the clinical endpoint were strongly associated with treatment effects on total slope (median R2=0.97 [95% Bayesian credible interval [BCI] 0.82 to 1.00]), and moderately associated with those on chronic slope (R2=0.55 [95% BCI 0.25 to 0.77]). There was no evidence of heterogeneity across disease. Our results support use of total slope as a primary endpoint for clinical trials of CKD progression.”
> “The slope of the meta-regression line is −0.35 (95% BCI −0.42 to −0.29) per mL/min per 1.73 m2/year), indicating that a 0.75 ml/min per 1.73 m2/year greater beneficial effect of the treatment on the total GFR slope is associated with an average 23.3% lower hazard ratio for the clinical end point (95% BCI 19.3% to 27.2%).”

Source: [Inker et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13037386/)

<a id="topic-3.1.1.6.1-10"></a>

###### Albuminuria and GFR slope as end points: NKF workshop with the FDA and EMA

> “The US Food and Drug Administration (FDA) and European Medicines Agency (EMA) are currently willing to consider a 30% to 40% glomerular filtration rate (GFR) decline as a surrogate end point for kidney failure for clinical trials of kidney disease progression under appropriate conditions.”
> “We conclude that both early change in albuminuria and GFR slope fulfill criteria for surrogacy for use as end points in clinical trials for chronic kidney disease progression under certain conditions, with stronger support for change in GFR than albuminuria.”

Source: [Levey et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/31473020/)

<a id="topic-3.1.1.6.1-11"></a>

###### GFR slope qualified by the EMA as a validated surrogate endpoint when clinical endpoints are not feasible

> “The proposed novel method, GFR slope, is qualified to be used as a validated surrogate endpoint for CKD progression in randomised controlled clinical trials to support marketing authorisation and extension of indication approvals when the use of clinical endpoints is not feasible due to rarity of the disease or need for a very long study period.”
> “An estimate of the treatment effect on GFR slope should be based on a sufficiently long-term evaluation period within a trial, preferably 3 years and usually at least 2 years.”

Source: [EMA qualification opinion for GFR slope (2023)](https://www.ema.europa.eu/en/documents/other/qualification-opinion-gfr-slope-validated-surrogate-endpoint-rct-ckd_en.pdf)

<a id="topic-3.1.1.6.1-12"></a>

###### Proteinuria reduction as a reasonably likely surrogate end point for accelerated approval: Kidney Health Initiative

> “In the United States, reasonably likely surrogate end points can be used as a basis for accelerated approval of therapies intended to treat serious or life-threatening conditions, such as IgAN. The clinical benefit of products approved under this program would need to be verified in a postmarketing confirmatory trial.”

Source: [Thompson et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6419287/)

<a id="topic-3.1.1.6.1-13"></a>

###### Proteinuria as an endpoint in focal segmental glomerulosclerosis: Kidney Health Initiative

> “Available data support the use of complete remission of proteinuria in patients with heavy proteinuria as a surrogate endpoint for progression to kidney failure. While substantial treatment effects on proteinuria that are short of a complete remission may also predict the effect of a treatment on progression to kidney failure, further work is needed to determine how such an endpoint should be defined.”

Source: [Mariani et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12014854/)

<a id="topic-3.1.1.6.1-14"></a>

###### Proteinuria reduction and kidney survival in steroid-resistant focal segmental glomerulosclerosis

> “A 1 unit reduction in log-transformed urinary protein:creatinine ratio was associated with a 3.90 ml/year rise in eGFR (95% CI=2.01 to 5.79).”
> “There was an analogous relationship between time-varying proteinuria and time to end-stage kidney disease: the HR for ESKD or death per 1 unit reduction in log-transformed urinary protein-creatinine ratio was 0.23 (95% CI=0.12 to 0.44).”

Source: [Troost et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7854818/)

<a id="topic-3.1.1.6.1-15"></a>

###### Albuminuria change as a surrogate endpoint across 48 randomized trials

> “Across all trials, each 30% reduction in the geometric mean of the UACR in the treatment group relative to the control group was associated with an average of 19% lower hazard for the clinical endpoint (95% Bayesian credible interval (BCI): 5-30%); median coefficient of determination (R2) = 0.66 (95% BCI: 0.06-0.98).”

Source: [Heerspink et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41198855/)

<a id="topic-3.1.1.6.1-16"></a>

###### Albuminuria change as a surrogate endpoint in APOL1-mediated kidney disease: real-world cohort preprint

> “However, proteinuria has not been evaluated in Apolipoprotein L1 (APOL1)-mediated kidney disease (AMKD).”
> “It was estimated that a 50% reduction of UACR at 12 months was associated with a 28% reduction in the kidney composite endpoint (adjusted hazard ratio [aHR]=0.72; 95% confidence interval [CI]:0.59−0.88; p=0.002), and a 38% reduction in the risk of ESKD (aHR=0.62; 95% CI:0.49−0.80; p<0.001).”
> “Changes in UACR at 12 months significantly modify the rate of decline of GFR over 24 months and clinically meaningful endpoints, supporting the use of UACR changes as surrogate endpoint in AMKD.”

Source: [Mamak et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13278290/)

<a id="topic-3.1.1.6.1-17"></a>

###### Regulatory precedent in focal segmental glomerulosclerosis: FDA approval to reduce proteinuria

> “Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced that the U.S. Food and Drug Administration (FDA) has approved FILSPARI® (sparsentan) to reduce proteinuria in adult and pediatric patients aged 8 years and older with focal segmental glomerulosclerosis (FSGS) without nephrotic syndrome.”

Source: [Travere Therapeutics press release, FILSPARI FSGS approval (2026)](https://www.businesswire.com/news/home/20260413839195/en/)

<a id="heading-3.1.1.7"></a>

##### 3.1.1.7 Statistical Analysis Description

<a id="heading-3.1.1.7.1"></a>

###### 3.1.1.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.1.7.1-1"></a>

###### Planned enrollment in the phase 2 and phase 3 portions

> “Approximately 66 patients are planned to be enrolled in the Phase 2 dose-ranging portion of the study, and approximately 400 additional patients are planned to be enrolled in the Phase 3 portion of the study.”

Source: [Vertex Pharmaceuticals press release, Breakthrough Therapy and PRIME designations (2022)](https://news.vrtx.com/news-releases/news-release-details/vertex-announces-inaxaplin-vx-147-granted-breakthrough-therapy)

<a id="topic-3.1.1.7.1-2"></a>

###### Actual enrollment in the ClinicalTrials.gov record

> “Enrollment (Actual) 522”

Source: [ClinicalTrials.gov NCT05312879](https://clinicaltrials.gov/study/NCT05312879)

<a id="topic-3.1.1.7.1-3"></a>

###### Planned participants in the EU member states

> “Belgium: Ongoing, recruitment ended. Planned participants: 2”
> “France: Ongoing, recruitment ended. Planned participants: 40”

Source: [CTIS.eu 2024-515633-15-00](https://ctis.eu/trial/2024-515633-15-00)

<a id="topic-3.1.1.7.1-4"></a>

###### Participants dosed in the phase 2 portion

> “Among 64 participants dosed, 34 (53.1%), 24 (37.5%), and 6 (9.4%) have G1/G1, G1/G2, or G2/G2 genotypes, respectively.”

Source: [Chertow et al. (2025a)](https://doi.org/10.1093/ndt/gfaf116.0477)

<a id="topic-3.1.1.7.1-5"></a>

###### Interim analysis cohort: a pre-specified number of participants at week 48

> “The AMPLITUDE study is designed with an interim analysis at Week 48 in a pre-specified number of patients to assess percent change from baseline in proteinuria and eGFR slope in the inaxaplin arm versus placebo.”

Source: [Vertex Pharmaceuticals press release, kidney portfolio advancements (2025)](https://news.vrtx.com/news-releases/news-release-details/vertex-announces-key-advancements-across-kidney-portfolio)

<a id="topic-3.1.1.7.1-6"></a>

###### Number of composite clinical outcomes required for the final analysis

> “The final study analysis will occur when subjects have at least two years of eGFR data and when approximately 187 composite clinical outcomes have occurred.”

Source: [Vertex Pharmaceuticals press release, Breakthrough Therapy and PRIME designations (2022)](https://news.vrtx.com/news-releases/news-release-details/vertex-announces-inaxaplin-vx-147-granted-breakthrough-therapy)

<a id="heading-3.1.1.7.2"></a>

###### 3.1.1.7.2 Description of Analysis Sets

<a id="topic-3.1.1.7.2-1"></a>

###### Interim analysis after the interim analysis cohort reaches 48 weeks of treatment

> “Vertex remains on track to conduct the pre-planned IA for potential U.S. accelerated approval after the IA cohort reaches 48 weeks of treatment and to share data from the IA in early 2027.”

Source: [Vertex Pharmaceuticals third quarter 2026 results (2026)](https://www.sec.gov/Archives/edgar/data/875320/000087532026000287/ex-991_q32026.htm)

<a id="topic-3.1.1.7.2-2"></a>

###### Interim analysis cohort limited to participants with primary AMKD

> “In September, Vertex completed enrollment in the interim analysis cohort of the AMPLITUDE Phase 2/3 trial of inaxaplin in patients with primary AMKD and will conduct the pre-planned interim analysis once this cohort reaches 48 weeks of treatment.”

Source: [Vertex Pharmaceuticals press release, pipeline and business updates (2026)](https://news.vrtx.com/news-releases/news-release-details/vertex-provides-pipeline-and-business-updates-advance-upcoming-1)

<a id="topic-3.1.1.7.2-3"></a>

###### Duration of eGFR data at the interim and final analyses

> “eGFR slope (with ≥48 weeks of eGFR data assessed at the IA and at least 2 years of eGFR data assessed at the final analysis)”

Source: [CTIS.eu 2024-515633-15-00](https://ctis.eu/trial/2024-515633-15-00)

<a id="topic-3.1.1.7.2-4"></a>

###### Final analysis timing in the design abstract

> “Final analysis will occur when ≥2 years of eGFR data and ∼187 composite clinical outcomes are obtained.”

Source: [Chertow et al. (2025a)](https://doi.org/10.1093/ndt/gfaf116.0477)

<a id="heading-3.1.1.8"></a>

##### 3.1.1.8 Results

<a id="heading-3.1.1.8.1"></a>

###### 3.1.1.8.1 Participant Disposition

<a id="topic-3.1.1.8.1-1"></a>

###### APOL1 genotyping study used to identify candidates: interim analysis

> “Our genotyping study is enrolling up to 4000 participants of recent African ancestry with FSGS or nondiabetic kidney disease and UPCR ≥0.5 g/g.”
> “The genotyping study interim analysis included 2866 participants of whom 674 (23.5%) have 2 APOL1 variants; 164 of the 674 (24.3%) participants are from Europe. Of the 674 participants with 2 APOL1 variants in this study, 36 enrolled in the completed Phase 2 component of AMPLITUDE.”

Source: [Chertow et al. (2025a)](https://doi.org/10.1093/ndt/gfaf116.0477)

<a id="topic-3.1.1.8.1-2"></a>

###### Completion of enrollment in the phase 2 dose-ranging portion

> “Completed enrollment in the Phase 2B dose-ranging portion of the study of inaxaplin for the treatment of patients with AMKD.”

Source: [Vertex Pharmaceuticals press release, pipeline and business updates (2024)](https://news.vrtx.com/news-releases/news-release-details/vertex-provides-pipeline-and-business-updates-advance-upcoming)

<a id="topic-3.1.1.8.1-3"></a>

###### Completion of enrollment in the interim analysis cohort in September 2025

> “In September, Vertex completed enrollment in the interim analysis cohort of the AMPLITUDE Phase 2/3 trial of inaxaplin in patients with primary AMKD and will conduct the pre-planned interim analysis once this cohort reaches 48 weeks of treatment.”

Source: [Vertex Pharmaceuticals press release, pipeline and business updates (2026)](https://news.vrtx.com/news-releases/news-release-details/vertex-provides-pipeline-and-business-updates-advance-upcoming-1)

<a id="topic-3.1.1.8.1-4"></a>

###### Completion of full enrollment in 2026

> “Having completed enrollment in the interim analysis (IA) cohort of the AMPLITUDE pivotal study last year, Vertex has now completed full enrollment.”

Source: [Vertex Pharmaceuticals third quarter 2026 results (2026)](https://www.sec.gov/Archives/edgar/data/875320/000087532026000287/ex-991_q32026.htm)

> “We have completed full enrollment in the AMPLITUDE pivotal clinical trial evaluating inaxaplin.”

Source: [Vertex Pharmaceuticals Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/875320/000087532026000291/vrtx-20260930.htm)

<a id="topic-3.1.1.8.1-5"></a>

###### Enrollment and recruitment status in the ClinicalTrials.gov record

> “Enrollment (Actual) 522”
> “No longer looking for participants”

Source: [ClinicalTrials.gov NCT05312879](https://clinicaltrials.gov/study/NCT05312879)

<a id="heading-3.1.1.8.2"></a>

###### 3.1.1.8.2 Baseline Characteristics

<a id="topic-3.1.1.8.2-1"></a>

###### Phase 2 portion: APOL1 genotype, age, and eGFR of 64 dosed participants

> “Among 64 participants dosed, 34 (53.1%), 24 (37.5%), and 6 (9.4%) have G1/G1, G1/G2, or G2/G2 genotypes, respectively. The mean (SD) age was 42.7 (11.0) years and mean (SD) baseline eGFR was 42.8 (14.0) mL/min/1.73 m2.”

Source: [Chertow et al. (2025a)](https://doi.org/10.1093/ndt/gfaf116.0477)

Additional sources: [Chertow et al. (2024)](https://www.ovid.com/jnls/jasn/fulltext/10.1681/asn.20241x7qn0bv~amplitude-a-phase-23-adaptive-trial-of-inaxaplin-in)

<a id="heading-3.1.1.8.3"></a>

###### 3.1.1.8.3 Efficacy Results

<a id="topic-3.1.1.8.3-1"></a>

###### Interim analysis results not yet reported

> “Vertex remains on track to conduct the pre-planned IA for potential U.S. accelerated approval after the IA cohort reaches 48 weeks of treatment and to share data from the IA in early 2027.”

Source: [Vertex Pharmaceuticals third quarter 2026 results (2026)](https://www.sec.gov/Archives/edgar/data/875320/000087532026000287/ex-991_q32026.htm)

<a id="topic-3.1.1.8.3-2"></a>

###### No results posted in the registry

> “Summary of the results: not applicable: the trial has not ended.”
> “Other registries: ClinicalTrials.gov NCT05312879: no results posted.”

Source: [CTIS.eu 2024-515633-15-00](https://ctis.eu/trial/2024-515633-15-00)

<a id="heading-3.1.1.8.4"></a>

###### 3.1.1.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.1.8.5"></a>

###### 3.1.1.8.5 Safety Results

No evidence found.

<a id="heading-3.1.1.9"></a>

##### 3.1.1.9 Study Limitations

<a id="topic-3.1.1.9-1"></a>

###### Summary: study limitations

As of November 2026, no efficacy or safety results of AMPLITUDE have been published or posted: the registry record shows 522 participants enrolled, and the company states that data from the week 48 interim analysis are expected in early 2027. The only participant-level data reported are the APOL1 genotype distribution, mean age (42.7 years), and mean eGFR (42.8 mL/min/1.73 m2) of the 64 participants dosed as of the 2025 abstract; the dose-selection results of that portion and its safety data have not been reported. The accelerated approval pathway rests on the week 48 interim analysis of percent change in UPCR and eGFR slope, two surrogate endpoints; the final analysis of eGFR slope requires at least 2 years of eGFR data, and the composite clinical outcome (sustained eGFR decline of at least 30%, end-stage kidney disease, or death) is a secondary endpoint. The supporting surrogate-endpoint evidence comes mainly from other kidney diseases: the EMA notes that for rare diseases “support of efficacy may need to be provided by additional endpoints”, a 2025 review states for proteinuria short of complete remission in FSGS that “further work is needed to determine how such an endpoint should be defined”, and the only analysis specific to APOL1-mediated kidney disease is a real-world analysis of 128 participants. Eligibility required UPCR of 0.7 to less than 10 g/g and eGFR of 25 to less than 75 mL/min/1.73 m2 and excluded people with diabetes, transplantation, uncontrolled hypertension, or another known cause of kidney disease, so the results will not describe people with modest proteinuria or type 2 diabetes, whom the company describes as “populations not being studied in the AMPLITUDE trial”. The registered age range differs between records: the ClinicalTrials.gov record lists 10 to 65 years, and the EU register inclusion criteria list 12 to 65 years for phase 3. The registry lists 314 locations in 13 countries and territories, including the United States. In Part B, participants who complete Part A receive inaxaplin for an additional 96 weeks without a placebo group, and the definitions of the analysis populations have not been published.

Source: [ClinicalTrials.gov NCT05312879](https://clinicaltrials.gov/study/NCT05312879); [CTIS.eu 2024-515633-15-00](https://ctis.eu/trial/2024-515633-15-00); [Vertex Pharmaceuticals third quarter 2026 results (2026)](https://www.sec.gov/Archives/edgar/data/875320/000087532026000287/ex-991_q32026.htm); [Vertex Pharmaceuticals press release, AMPLIFIED results (2026)](https://news.vrtx.com/news-releases/news-release-details/vertex-announces-positive-results-phase-2b-amplified-study); [Vertex Pharmaceuticals press release, Breakthrough Therapy and PRIME designations (2022)](https://news.vrtx.com/news-releases/news-release-details/vertex-announces-inaxaplin-vx-147-granted-breakthrough-therapy); [Chertow et al. (2025a)](https://doi.org/10.1093/ndt/gfaf116.0477); [EMA qualification opinion for GFR slope (2023)](https://www.ema.europa.eu/en/documents/other/qualification-opinion-gfr-slope-validated-surrogate-endpoint-rct-ckd_en.pdf); [Mariani et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12014854/); [Mamak et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13278290/)

<a id="topic-3.1.1.9-2"></a>

###### Populations not studied in AMPLITUDE

> “AMPLIFIED is a Phase 2, single-arm, open-label study evaluating the effect of treatment with a 45 mg once-daily dose of inaxaplin for 13 weeks to reduce proteinuria in people with AMKD with modest proteinuria, and people with AMKD and type 2 diabetes”
> “populations not being studied in the AMPLITUDE trial.”

Source: [Vertex Pharmaceuticals press release, AMPLIFIED results (2026)](https://news.vrtx.com/news-releases/news-release-details/vertex-announces-positive-results-phase-2b-amplified-study)

<a id="topic-3.1.1.9-3"></a>

###### Surrogacy of GFR slope in rare diseases may need support from additional endpoints

> “For rare diseases and disease entities with less weight in the trial-level surrogacy analysis, considerations may differ, and support of efficacy may need to be provided by additional endpoints and/or demonstration of lack of a detrimental effect.”
> “In the presence of large acute effects, GFR slope might not be suitable as a surrogate endpoint.”

Source: [EMA qualification opinion for GFR slope (2023)](https://www.ema.europa.eu/en/documents/other/qualification-opinion-gfr-slope-validated-surrogate-endpoint-rct-ckd_en.pdf)

<a id="topic-3.1.1.9-4"></a>

###### Accelerated approval requires verification of clinical benefit

> “the FDA has generally required post-marketing studies to verify and describe the clinical benefit of products approved under the accelerated approval pathway”

Source: [Mariani et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12014854/)

<a id="heading-3.1.2"></a>

#### 3.1.2 VX19-147-101

<a id="heading-3.1.2.1"></a>

##### 3.1.2.1 Objective

<a id="topic-3.1.2.1-1"></a>

###### Purpose stated in the ClinicalTrials.gov brief summary

> “This study will evaluate the efficacy, safety and pharmacokinetics (PK) of VX-147 in participants with apolipoprotein L1 (APOL1)-mediated focal segmental glomerulosclerosis (FSGS).”
> “A Phase 2a, Open-label, Single-arm, 2-Part Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of VX-147 in Adults With APOL1-mediated Focal Segmental Glomerulosclerosis”

Source: [ClinicalTrials.gov NCT04340362](https://clinicaltrials.gov/study/NCT04340362)

<a id="topic-3.1.2.1-2"></a>

###### Primary, secondary, and exploratory objectives in the protocol

> “To evaluate the ability of VX-147 to reduce proteinuria”
> “To evaluate the safety and tolerability of VX-147”
> “To characterize the PK of VX-147”
> “To evaluate the change in proteinuria after stopping administration of VX-147”

Source: [Vertex Pharmaceuticals VX19-147-101 protocol (2021)](https://cdn.clinicaltrials.gov/large-docs/62/NCT04340362/Prot_000.pdf)

<a id="topic-3.1.2.1-3"></a>

###### Aim of part A and part B in the published report

> “Part A of the phase 2a study was designed to evaluate the ability of inaxaplin to reduce proteinuria.”
> “After the completion of inaxaplin treatment in part A, participants had the option to enroll in part B, which was designed to explore the percent change in proteinuria for up to 12 weeks after the completion of treatment in part A.”

Source: [Egbuna et al. (2023)](https://www.nejm.org/doi/full/10.1056/NEJMoa2202396)

<a id="topic-3.1.2.1-4"></a>

###### Proof-of-concept purpose stated in the protocol

> “This study is a Phase 2a proof-of-concept study designed to assess the efficacy effects, safety, and pharmacokinetics (PK) of VX-147 in subjects with APOL1-mediated FSGS.”

Source: [Vertex Pharmaceuticals VX19-147-101 protocol (2021)](https://cdn.clinicaltrials.gov/large-docs/62/NCT04340362/Prot_000.pdf)

<a id="heading-3.1.2.2"></a>

##### 3.1.2.2 Location and Study Date

<a id="topic-3.1.2.2-1"></a>

###### Study dates and status in the ClinicalTrials.gov record

> “Study Start (Actual) 2020-06-08”
> “Primary Completion (Actual) 2021-11-11”
> “Study Completion (Actual) 2021-12-09”
> “Results First Posted 2023-07-10”

Source: [ClinicalTrials.gov NCT04340362](https://clinicaltrials.gov/study/NCT04340362)

<a id="topic-3.1.2.2-2"></a>

###### Registered locations

> “This study has 44 locations”

Source: [ClinicalTrials.gov NCT04340362](https://clinicaltrials.gov/study/NCT04340362)

<a id="topic-3.1.2.2-3"></a>

###### Sites, countries, and enrollment period in the published report

> “We then conducted a two-part, single-group, open-label, phase 2a clinical study (VX19-147-101) at 12 sites in France, the United Kingdom, and the United States.”
> “Study enrollment began in September 2020 and was completed in August 2021.”

Source: [Egbuna et al. (2023)](https://www.nejm.org/doi/full/10.1056/NEJMoa2202396)

<a id="topic-3.1.2.2-4"></a>

###### Other study identifiers

> “VX19-147-101”
> “2020-000185-42 ( EudraCT Number )”

Source: [ClinicalTrials.gov NCT04340362](https://clinicaltrials.gov/study/NCT04340362)

<a id="heading-3.1.2.3"></a>

##### 3.1.2.3 Study Design

<a id="topic-3.1.2.3-1"></a>

###### Single-group, open-label, two-part design

> “We then conducted a two-part, single-group, open-label, phase 2a clinical study (VX19-147-101) at 12 sites in France, the United Kingdom, and the United States.”
> “Participants were enrolled into one of two groups on the basis of the degree of proteinuria (nephrotic or subnephrotic range) at screening and received inaxaplin treatment for 13 weeks (15 mg once daily for 2 weeks, followed by 45 mg once daily for 11 weeks) (Fig. S2).”
> “A safety follow-up visit was required 28 days (within a window of ±7 days) after the receipt of the last dose of inaxaplin.”

Source: [Egbuna et al. (2023)](https://www.nejm.org/doi/full/10.1056/NEJMoa2202396)

<a id="topic-3.1.2.3-2"></a>

###### Design details in the ClinicalTrials.gov record

| Field | Quoted record |
| --- | --- |
| Primary purpose | “Treatment” |
| Allocation | “N/A” |
| Interventional model | “Single Group Assignment” |
| Masking | “None (Open Label)” |
| Phase | “Phase 2” |
| Enrollment | “16” |

Source: [ClinicalTrials.gov NCT04340362](https://clinicaltrials.gov/study/NCT04340362)

<a id="topic-3.1.2.3-3"></a>

###### Cohorts defined by proteinuria at screening in the protocol

> “This is a single-arm, open-label, 2-part study. In Part A, subjects will receive VX-147 at a dosage of 15 mg once daily (qd) for 2 weeks and VX-147 at a dosage of 45 mg qd for 11 weeks.”
> “Cohort 1 includes up to 10 subjects with UPCR approximately ≥3 g/g and <10 g/g and eGFR approximately ≥30 mL/min/1.73 m2. Optional Cohort 2 includes approximately 10 subjects with UPCR approximately ≥0.8 g/g and <2.7 g/g and eGFR approximately ≥30 mL/min/1.73 m2.”

Source: [Vertex Pharmaceuticals VX19-147-101 protocol (2021)](https://cdn.clinicaltrials.gov/large-docs/62/NCT04340362/Prot_000.pdf)

<a id="topic-3.1.2.3-4"></a>

###### Part B off-treatment follow-up

> “After completing Part A, subjects will be followed for up to 12 weeks in Part B (optional) for evaluation of proteinuria off treatment if they consent to do so.”
> “All subjects are required to complete a SFUV at 28 (± 7) days after the last dose of study drug. The SFUV may occur while a subject is participating in Part B.”

Source: [Vertex Pharmaceuticals VX19-147-101 protocol (2021)](https://cdn.clinicaltrials.gov/large-docs/62/NCT04340362/Prot_000.pdf)

<a id="topic-3.1.2.3-5"></a>

###### Rationale for omitting a placebo group and for the 13-week duration

> “A placebo arm was not included because FSGS is a rare, severe disease with a very low likelihood of spontaneous remission.”
> “The duration of 13 weeks for this study was selected to allow the maximum treatment time supported by nonclinical data.”

Source: [Vertex Pharmaceuticals VX19-147-101 protocol (2021)](https://cdn.clinicaltrials.gov/large-docs/62/NCT04340362/Prot_000.pdf)

<a id="topic-3.1.2.3-6"></a>

###### Partially decentralized conduct

> “The present phase 2a clinical study was designed as a partially decentralized study in order to minimize the burden to participants. With our study design, participants had the option to complete assessments on-site or at home with a visiting nurse, a factor that enabled successful completion of the study, especially during the coronavirus disease 2019 pandemic.”

Source: [Egbuna et al. (2023)](https://www.nejm.org/doi/full/10.1056/NEJMoa2202396)

<a id="topic-3.1.2.3-7"></a>

###### Study design and oversight

> “The study was designed by the sponsor in collaboration with the steering committee.”
> “Data collection was performed by the sponsor and the VX19-147-101 Study Group; data analysis was performed by the sponsor in collaboration with the steering committee.”

Source: [Egbuna et al. (2023)](https://www.nejm.org/doi/full/10.1056/NEJMoa2202396)

<a id="heading-3.1.2.4"></a>

##### 3.1.2.4 Eligibility Criteria

<a id="topic-3.1.2.4-1"></a>

###### Key eligibility criteria in the published report

> “We enrolled adult participants 18 to 65 years of age who had a body weight of more than 50 kg, a body-mass index (the weight in kilograms divided by the square of the height in meters) of 18.0 to 40.0, biopsy-proven focal segmental glomerulosclerosis, two APOL1 variants (G1 and G1, G2 and G2, or G1 and G2), and nephrotic- or subnephrotic-range proteinuria.”
> “Nephrotic-range proteinuria was defined as a urinary protein-to-creatinine ratio (with protein and creatinine both measured in grams) of at least 2.7 and less than 10, and subnephrotic-range proteinuria as a urinary protein-to-creatinine ratio of at least 0.7 and less than 2.7.”
> “All the participants had an estimated glomerular filtration rate (GFR) of at least 27 ml per minute per 1.73 m2 of body-surface area (on the basis of the 2009 Chronic Kidney Disease Epidemiology Collaboration estimating equation for estimated GFR, which includes a coefficient for race).”

Source: [Egbuna et al. (2023)](https://www.nejm.org/doi/full/10.1056/NEJMoa2202396)

<a id="topic-3.1.2.4-2"></a>

###### APOL1 genotyping assay

> “APOL1 genotyping was performed with the use of in vitro diagnostic assay developed by Vertex Pharmaceuticals (the sponsor) and LabCorp. This assay consists of two real-time polymerase-chain-reaction assays that use Taqman to detect the G1 and G2 variants in whole-blood samples.”

Source: [Egbuna et al. (2023)](https://www.nejm.org/doi/full/10.1056/NEJMoa2202396)

<a id="topic-3.1.2.4-3"></a>

###### Key inclusion and exclusion criteria in the ClinicalTrials.gov record

> “APOL1 genotype of G1/G1, G2/G2, or G1/G2”
> “FSGS diagnosed by kidney biopsy”
> “Evidence of non-APOL1-mediated FSGS”
> “Participants with known sickle cell disease”
> “Solid organ or Bone marrow transplant”
> “18 Years to 65 Years (Adult, Older Adult )”

Source: [ClinicalTrials.gov NCT04340362](https://clinicaltrials.gov/study/NCT04340362)

<a id="topic-3.1.2.4-4"></a>

###### Inclusion criteria in the protocol: biopsy, stable background therapy, eGFR, and UPCR

> “FSGS diagnosed by kidney biopsy, with the exception of the tip variant, as confirmed through the eligibility review process.”
> “Subjects who are on low-dose corticosteroids (prednisone ≤ 10 mg per day or prednisone equivalent) or on an allowed immunosuppressant (i.e. tacrolimus, mycophenolate, or cyclosporine) must be on a stable dose for 28 days before screening.”
> “Estimated glomerular filtration rate (eGFR) ≥30 mL/min/1.73 m2 (±10%) based on the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation.”
> “Subjects with eGFR ≥30 (±10%) to <40 mL/min/1.73 m2 must have tubulointerstitial fibrosis ≤50% or described as no, mild, or moderate on their kidney biopsy.”
> “A UPCR ratio of ≥3 g/g (±10%) and <10 g/g in the first morning void on 3 measurements collected on at least 3 separate days within a 7-day period, during the Screening Period.”
> “A UPCR ratio of ≥0.8 g/g (±10%) and <2.7 g/g in the first morning void on 3 measurements collected on at least 3 separate days within a 7-day period, during the Screening Period.”

Source: [Vertex Pharmaceuticals VX19-147-101 protocol (2021)](https://cdn.clinicaltrials.gov/large-docs/62/NCT04340362/Prot_000.pdf)

<a id="topic-3.1.2.4-5"></a>

###### Exclusion criteria in the protocol: non-APOL1 causes of FSGS and other conditions

> “FSGS occurring in a subject with known sickle cell disease.”
> “Known genetic mutation other than APOL1 G1 or G2 that is associated with FSGS.”
> “Positive serology for human immunodeficiency virus-1 (HIV-1) or human immunodeficiency virus-2 (HIV-2).”
> “Kidney biopsy showing the tip variant of FSGS, as assessed by the eligibility review process.”
> “Screening blood pressure ≥160 mm Hg (systolic) or ≥100 mm Hg (diastolic), based on the average of 3 measurements.”
> “Plan to travel to countries where sleeping sickness is endemic, from the Screening Visit through 1 week after the last dose of study drug.”

Source: [Vertex Pharmaceuticals VX19-147-101 protocol (2021)](https://cdn.clinicaltrials.gov/large-docs/62/NCT04340362/Prot_000.pdf)

<a id="heading-3.1.2.5"></a>

##### 3.1.2.5 Treatment

<a id="topic-3.1.2.5-1"></a>

###### Inaxaplin dosing regimen

> “Participants received inaxaplin daily for 13 weeks (15 mg for 2 weeks and 45 mg for 11 weeks) along with standard care.”

Source: [Egbuna et al. (2023)](https://www.nejm.org/doi/full/10.1056/NEJMoa2202396)

<a id="topic-3.1.2.5-2"></a>

###### Intervention in the ClinicalTrials.gov record

> “All participants received VX-147 at a dosage of 15 mg once daily (qd) for 2 weeks and VX-147 at a dosage of 45 mg qd for 11 weeks.”
> “Tablets for oral administration.”

Source: [ClinicalTrials.gov NCT04340362](https://clinicaltrials.gov/study/NCT04340362)

<a id="topic-3.1.2.5-3"></a>

###### Administration instructions in the protocol

> “VX-147 will be administered as 15 mg tablets, orally, as shown in Table 3-2.”
> “Study drug may be taken with or without food.”
> “Subjects will swallow the study drug whole, with a full glass of water and will not chew it before swallowing.”
> “No dose modifications are allowed.”

Source: [Vertex Pharmaceuticals VX19-147-101 protocol (2021)](https://cdn.clinicaltrials.gov/large-docs/62/NCT04340362/Prot_000.pdf)

<a id="topic-3.1.2.5-4"></a>

###### Rationale for the 15 mg and 45 mg doses

> “The 2-week duration for the 15 mg qd dose was selected based on an exposure-response model suggesting that a measurable decrease in proteinuria may be observed after 2 weeks of dosing.”
> “A high dose of 45 mg once daily is selected to maximize the probability of reduction in proteinuria over the 11-week dosing period.”

Source: [Vertex Pharmaceuticals VX19-147-101 protocol (2021)](https://cdn.clinicaltrials.gov/large-docs/62/NCT04340362/Prot_000.pdf)

<a id="topic-3.1.2.5-5"></a>

###### Background standard care

> “Participants were required to continue taking stable doses of standard-care medications from at least 28 days before commencing inaxaplin through follow-up. Such medications could include, but were not limited to, systemic glucocorticoids (prednisone at a dose of ≤10 mg per day or equivalent), immunosuppressants (tacrolimus, cyclosporine, or mycophenolate mofetil), and renin–angiotensin–aldosterone inhibitors.”

Source: [Egbuna et al. (2023)](https://www.nejm.org/doi/full/10.1056/NEJMoa2202396)

<a id="topic-3.1.2.5-6"></a>

###### Restricted medications and foods in the protocol

> “Moderate and strong CYP3A4 inhibitors or inducers, including consumption of herbal medications (e.g., St. John’s Wort)”
> “None allowed within 14 days before the first dose of the study drug”
> “Grapefruit, grapefruit juice, pomelos, orange marmalade, Seville/blood oranges”

Source: [Vertex Pharmaceuticals VX19-147-101 protocol (2021)](https://cdn.clinicaltrials.gov/large-docs/62/NCT04340362/Prot_000.pdf)

<a id="topic-3.1.2.5-7"></a>

###### Travel restriction

> “As a condition of participation in the study, we prohibited travel during the study to countries where African sleeping sickness (African trypanosomiasis) is endemic.”

Source: [Egbuna et al. (2023)](https://www.nejm.org/doi/full/10.1056/NEJMoa2202396)

<a id="heading-3.1.2.6"></a>

##### 3.1.2.6 Study Outcomes

<a id="heading-3.1.2.6.1"></a>

###### 3.1.2.6.1 Rationale for Using Percent Change in UPCR as the Primary Endpoint

<a id="topic-3.1.2.6.1-1"></a>

###### Primary and secondary outcomes

> “The primary efficacy outcome was the percent change from the baseline urinary protein-to-creatinine ratio at week 13. Secondary outcomes included safety and pharmacokinetics. The safety analysis was based on adverse events, clinical laboratory values, standard 12-lead electrocardiograms, and vital signs.”

Source: [Egbuna et al. (2023)](https://www.nejm.org/doi/full/10.1056/NEJMoa2202396)

<a id="topic-3.1.2.6.1-2"></a>

###### Registered primary and secondary outcome measures

> “Percent Change From Baseline in UPCR”
> “From Baseline up to Week 13”
> “Safety and Tolerability as Assessed by Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)”
> “Maximum Observed Concentration (Cmax) of VX-147”
> “Observed Pre-dose Concentration (Ctrough) of VX-147”
> “Area Under the Concentration Time-curve From 0 to 24 Hours (AUC0-24hr) of VX-147”

Source: [ClinicalTrials.gov NCT04340362](https://clinicaltrials.gov/study/NCT04340362)

<a id="topic-3.1.2.6.1-3"></a>

###### Exploratory endpoints in the protocol

> “Percent change from baseline in urine albumin-to-creatinine ratio (UACR) at Week 13”
> “Change from baseline in patient-reported outcome (PRO) Short Form Health Survey 36 (SF-36) over time during the Treatment Period”
> “Percent change from baseline in UPCR at the end of the Off-treatment Follow-up Period”

Source: [Vertex Pharmaceuticals VX19-147-101 protocol (2021)](https://cdn.clinicaltrials.gov/large-docs/62/NCT04340362/Prot_000.pdf)

<a id="topic-3.1.2.6.1-4"></a>

###### Sponsor rationale for UPCR as the primary endpoint and its measurement

> “Percent change from baseline in UPCR at Week 13 was chosen as the primary endpoint because proteinuria is a characteristic feature of FSGS and 1 of its main prognostic factors.”
> “As UPCR is variable within an individual, 3 samples will be taken during screening, Week 5, Week 9, and Week 13; and the average of the 3 values will be used to determine baseline, Week 5, Week 9, and end-of-treatment UPCR values, respectively.”

Source: [Vertex Pharmaceuticals VX19-147-101 protocol (2021)](https://cdn.clinicaltrials.gov/large-docs/62/NCT04340362/Prot_000.pdf)

<a id="topic-3.1.2.6.1-5"></a>

###### Proteinuria and progression to end-stage kidney disease

> “Among patients with CKD, including those with two APOL1 variants, the degree of proteinuria is directly associated with the likelihood of progression to end-stage kidney disease, and several agents that reduce proteinuria have been shown to attenuate CKD progression and reduce the risk of cardiovascular events.”

Source: [Egbuna et al. (2023)](https://www.nejm.org/doi/full/10.1056/NEJMoa2202396)

<a id="topic-3.1.2.6.1-6"></a>

###### Threshold for a clinically meaningful reduction in proteinuria

> “A reduction in proteinuria or albuminuria of more than 40% is considered to be clinically meaningful on the basis of data from nearly 30,000 patients, in whom a 30% reduction in albuminuria translated to a 27% reduction in the risk of a composite clinical end point of end-stage kidney disease, an estimated GFR below 15 ml per minute per 1.73 m2, or a doubling of the serum creatinine level (57% reduction in the estimated GFR).”
> “Collectively, these data provide a rationale to test the hypothesis that with a longer treatment period, inaxaplin therapy may prevent or slow progression to end-stage kidney disease.”

Source: [Egbuna et al. (2023)](https://www.nejm.org/doi/full/10.1056/NEJMoa2202396)

<a id="topic-3.1.2.6.1-7"></a>

###### Placebo response in proteinuric CKD trials

> “In participants who received placebo in placebo-controlled trials involving patients with proteinuric CKD, reductions of up to 15% in the urinary protein-to-creatinine ratio have been observed,37,38 a treatment effect that is much smaller than what we observed in this study.”

Source: [Egbuna et al. (2023)](https://www.nejm.org/doi/full/10.1056/NEJMoa2202396)

<a id="topic-3.1.2.6.1-8"></a>

###### Commentary on proteinuria reduction as an endpoint

> “The degree of proteinuria reduction achieved in the phase 2A clinical trial has been shown to be associated with slowing the progression of proteinuric kidney disease and it is unlikely to be an artefact of being enrolled in a clinical trial”

Source: [Gbadegesin et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10461697/)

<a id="heading-3.1.2.7"></a>

##### 3.1.2.7 Statistical Analysis Description

<a id="heading-3.1.2.7.1"></a>

###### 3.1.2.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.2.7.1-1"></a>

###### Planned enrollment in the protocol

> “Up to 10 subjects in Cohort 1 and approximately 10 subjects in optional Cohort 2”

Source: [Vertex Pharmaceuticals VX19-147-101 protocol (2021)](https://cdn.clinicaltrials.gov/large-docs/62/NCT04340362/Prot_000.pdf)

<a id="topic-3.1.2.7.1-2"></a>

###### Sample size based on precision of the estimate

> “The sample size was selected on the basis of the precision of the expected estimator. Assuming a standard deviation of 0.672 (in log scale), we calculated that a sample size of 10 would provide the study with a precision of 0.294 (in log scale) for the estimation of the geometric mean percent change from baseline in the urinary protein-to-creatinine ratio.”
> “Although we did not determine a sample size on the basis of power calculations, we anticipated a relatively large reduction in proteinuria and believed that the selected sample size on the basis of precision estimation would be sufficient to determine the range of proteinuria reduction that could inform the design of subsequent, longer-term, placebo-controlled trials.”

Source: [Egbuna et al. (2023)](https://www.nejm.org/doi/full/10.1056/NEJMoa2202396)

<a id="topic-3.1.2.7.1-3"></a>

###### Participants enrolled and analyzed

> “Sixteen participants were enrolled in the phase 2a study.”
> “Among the 16 participants, 3 did not have at least 80% adherence to treatment and were therefore not included in the primary efficacy analyses, as prespecified in the statistical analysis plan (see the Supplementary Appendix).”
> “As compared with the baseline reduction in proteinuria that was observed at the end of part A of the study, in the exploratory part B of the study (in which data from nine participants were assessed), the mean urinary protein-to-creatinine ratio increased from −47.6% to −30.1% at week 4.”

Source: [Egbuna et al. (2023)](https://www.nejm.org/doi/full/10.1056/NEJMoa2202396)

<a id="topic-3.1.2.7.1-4"></a>

###### Participants by cohort in the posted results

| Measure | Quoted record |
| --- | --- |
| Enrollment (actual) | “16” |
| Started | “16” |
| Cohort 1 | “3” |
| Cohort 2 | “13” |
| AUC0-24hr, overall number of participants analyzed | “13” |

Source: [ClinicalTrials.gov NCT04340362 results](https://clinicaltrials.gov/study/NCT04340362?tab=results)

<a id="heading-3.1.2.7.2"></a>

###### 3.1.2.7.2 Description of Analysis Sets

<a id="topic-3.1.2.7.2-1"></a>

###### Primary efficacy analysis restricted to participants with at least 80% adherence

> “As prespecified in the statistical analysis plan (which is available with the protocol), the primary efficacy analysis included all the participants who had at least 80% adherence to inaxaplin treatment. We also report the results of efficacy analyses that included all the participants regardless of treatment adherence.”
> “Safety analyses included all the participants who received at least one dose of inaxaplin; safety data were summarized with the use of descriptive statistics.”

Source: [Egbuna et al. (2023)](https://www.nejm.org/doi/full/10.1056/NEJMoa2202396)

<a id="topic-3.1.2.7.2-2"></a>

###### Analysis sets defined in the statistical analysis plan

> “The Full Analysis Set (FAS) will include all subjects who received at least 1 dose of study drug in the Treatment Period and with at least 1 post-baseline efficacy assessment.”
> “The Follow-up Set will include all subjects who entered the Off-treatment Follow-up Period (Part B) and have at least 1 efficacy assessment in that period.”
> “The Safety Set will include all subjects who received at least 1 dose of study drug.”
> “Subjects non-compliant with study drug will not be included in the analysis.”

Source: [Vertex Pharmaceuticals VX19-147-101 statistical analysis plan (2021)](https://cdn.clinicaltrials.gov/large-docs/62/NCT04340362/SAP_001.pdf)

<a id="topic-3.1.2.7.2-3"></a>

###### Analysis populations in the posted results

> “All participants who received at least one dose of the study drug during the treatment period were included in the baseline analysis.”
> “The PK set included all those who received at least 1 dose of study drug.”

Source: [ClinicalTrials.gov NCT04340362 results](https://clinicaltrials.gov/study/NCT04340362?tab=results)

<a id="topic-3.1.2.7.2-4"></a>

###### Statistical methods for the primary endpoint: log-transformed geometric mean percent change

> “We calculated the urinary protein-to-creatinine ratio as the mean of the three values from first-morning void urine samples obtained within a 7-day window. To reduce skewness, we analyzed the percent change from the baseline urinary protein-to-creatinine ratio at week 13 by first log-transforming the data for the ratio before the analyses and then calculating the change from baseline in log-transformed values.”
> “We calculated the geometric mean percent change from the baseline urinary protein-to-creatinine ratio at week 13 and the corresponding two-sided confidence interval by back-transforming the estimated simple mean of the change from baseline in log-transformed data.”

Source: [Egbuna et al. (2023)](https://www.nejm.org/doi/full/10.1056/NEJMoa2202396)

<a id="topic-3.1.2.7.2-5"></a>

###### Statistical methods: confidence intervals, multiplicity, and sensitivity analyses in the statistical analysis plan

> “The GMPC from baseline in UPCR at Week 13, GSE (%), along with the corresponding 2-sided 80% CI will be provided. In addition, the corresponding 2-sided 95% CI will be provided for descriptive purposes.”
> “Multiplicity: No multiplicity adjustment will be performed.”
> “There will be no supportive analysis for the primary efficacy endpoint.”
> “No sensitivity analysis for the primary efficacy variable is planned.”

Source: [Vertex Pharmaceuticals VX19-147-101 statistical analysis plan (2021)](https://cdn.clinicaltrials.gov/large-docs/62/NCT04340362/SAP_001.pdf)

<a id="topic-3.1.2.7.2-6"></a>

###### Statistical methods: descriptive safety and pharmacokinetic analyses in the protocol

> “The safety analyses will be descriptive only.”
> “Noncompartmental analyses will be performed, and summary statistics will be provided for VX-147 PK parameters.”

Source: [Vertex Pharmaceuticals VX19-147-101 protocol (2021)](https://cdn.clinicaltrials.gov/large-docs/62/NCT04340362/Prot_000.pdf)

<a id="heading-3.1.2.8"></a>

##### 3.1.2.8 Results

<a id="heading-3.1.2.8.1"></a>

###### 3.1.2.8.1 Participant Disposition

<a id="topic-3.1.2.8.1-1"></a>

###### Participant flow in the posted results

| Milestone | Quoted record |
| --- | --- |
| Started | “16” |
| Cohort 1 | “3” |
| Cohort 2 | “13” |
| Completed | “15” |
| Not completed | “1” |
| Reason not completed | “Withdrawal of consent (not due to adverse event)” |

Source: [ClinicalTrials.gov NCT04340362 results](https://clinicaltrials.gov/study/NCT04340362?tab=results)

<a id="topic-3.1.2.8.1-2"></a>

###### Study parts covered by the posted results

> “This study was planned in 2 parts: Part A (Treatment Period), which consisted of 2 cohorts (i.e., cohort 1 and 2) and Part B (Optional Exploratory Off-treatment Follow-up Period). The primary and secondary efficacy analyses and safety analyses were planned for only Part A.”

Source: [ClinicalTrials.gov NCT04340362 results](https://clinicaltrials.gov/study/NCT04340362?tab=results)

<a id="topic-3.1.2.8.1-3"></a>

###### Exclusion of participants below the adherence threshold and part B participation

> “Among the 16 participants, 3 did not have at least 80% adherence to treatment and were therefore not included in the primary efficacy analyses, as prespecified in the statistical analysis plan (see the Supplementary Appendix).”
> “Finally, although just nine participants entered the optional extension of the study (part B), we were encouraged that the reduction in proteinuria was sustained after the completion of treatment in some participants.”

Source: [Egbuna et al. (2023)](https://www.nejm.org/doi/full/10.1056/NEJMoa2202396)

<a id="topic-3.1.2.8.1-4"></a>

###### Company statement on noncompliant participants

> “A total of 16 patients were enrolled in the study. According to the pre-specified statistical analysis plan, three patients who were noncompliant with treatment were not included in the primary efficacy analysis.”

Source: [Vertex Pharmaceuticals press release, phase 2 results (2021)](https://news.vrtx.com/news-releases/news-release-details/vertex-announces-positive-results-phase-2-study-vx-147-apol1)

<a id="heading-3.1.2.8.2"></a>

###### 3.1.2.8.2 Baseline Characteristics

<a id="topic-3.1.2.8.2-1"></a>

###### Demographic and clinical characteristics at baseline (Table 1)

| Characteristic | Total (N=16) | Nephrotic-range proteinuria (N=3) | Subnephrotic-range proteinuria (N=13) |
| --- | --- | --- | --- |
| Age, years, mean ±SD | “38.8±14.5” | “45.0±10.5” | “37.3±15.2” |
| Male, no. (%) | “7 (44)” | “1 (33)” | “6 (46)” |
| Female, no. (%) | “9 (56)” | “2 (67)” | “7 (54)” |
| APOL1 genotype G1/G1, no. (%) | “9 (56)” | “3 (100)” | “6 (46)” |
| APOL1 genotype G2/G2, no. (%) | “1 (6)” | “0” | “1 (8)” |
| APOL1 genotype G1/G2, no. (%) | “6 (38)” | “0” | “6 (46)” |
| Body-mass index, mean ±SD | “29.6±6.4” | “32.7±6.4” | “28.9±6.4” |
| Urinary protein-to-creatinine ratio, mean ±SD | “2.08±0.90” | “3.47±1.07” | “1.77±0.49” |
| Estimated GFR, ml/min/1.73 m2, mean ±SD | “51.2±14.0” | “51.4±22.2” | “51.2±12.8” |
| ACE inhibitor ≥28 days before day 1, no. (%) | “8 (50)” | “1 (33)” | “7 (54)” |
| Angiotensin-receptor blocker ≥28 days before day 1, no. (%) | “7 (44)” | “3 (100)” | “4 (31)” |
| Immunosuppressants ≥28 days before day 1, no. (%) | “4 (25)” | “1 (33)” | “3 (23)” |

Source: [Egbuna et al. (2023)](https://www.nejm.org/doi/full/10.1056/NEJMoa2202396)

<a id="topic-3.1.2.8.2-2"></a>

###### Immunosuppressants taken by participants

> “Immunosuppressants included systemic glucocorticoids. The following medications were taken by participants: prednisone (one participant), mycophenolate mofetil (one), and tacrolimus (two).”

Source: [Egbuna et al. (2023)](https://www.nejm.org/doi/full/10.1056/NEJMoa2202396)

<a id="topic-3.1.2.8.2-3"></a>

###### Baseline UPCR in the efficacy population and similarity across subgroups

> “The mean (±SD) age of the 16 enrolled participants was 38.8±14.5 years, and the mean baseline urinary protein-to-creatinine ratio was 2.08±0.90 among all the participants who had received at least one dose of inaxaplin and 2.21±0.95 among the 13 participants who were evaluable in the efficacy analysis (Table 2).”
> “The baseline characteristics of the participants, including the estimated GFR at baseline and the distribution of standard-care medications, were generally similar among the 3 participants with nephrotic-range proteinuria and the 13 with subnephrotic-range proteinuria and among the 13 participants who were included in the primary analysis and the 3 who were not.”

Source: [Egbuna et al. (2023)](https://www.nejm.org/doi/full/10.1056/NEJMoa2202396)

<a id="topic-3.1.2.8.2-4"></a>

###### Race and ethnicity in the posted results

| Characteristic | Cohort 1 (N=3) | Cohort 2 (N=13) |
| --- | --- | --- |
| Black or African American | “3” | “13” |
| White | “0” | “0” |
| Not Hispanic or Latino | “3” | “13” |

Source: [ClinicalTrials.gov NCT04340362 results](https://clinicaltrials.gov/study/NCT04340362?tab=results)

<a id="heading-3.1.2.8.3"></a>

###### 3.1.2.8.3 Efficacy Results

<a id="topic-3.1.2.8.3-1"></a>

###### Primary endpoint: percent change from baseline in UPCR at week 13 (Table 2)

| Measure | Total (N=13) | Nephrotic-range proteinuria (N=3) | Subnephrotic-range proteinuria (N=10) |
| --- | --- | --- | --- |
| Mean UPCR at baseline, ±SD | “2.21±0.95” | “3.47±1.07” | “1.84±0.52” |
| Mean UPCR at week 13, ±SD | “1.27±0.73” | “1.83±0.58” | “1.10±0.71” |
| Geometric percent change from baseline at week 13 (95% CI) | “−47.6 (−60.0 to −31.3)” | “−47.7 (−70.1 to −8.5)” | “−47.5(−63.4 to −24.6)” |

Source: [Egbuna et al. (2023)](https://www.nejm.org/doi/full/10.1056/NEJMoa2202396)

<a id="topic-3.1.2.8.3-2"></a>

###### Primary endpoint in the published abstract

> “Among the 13 participants who were treated with inaxaplin and met the adherence threshold, the mean change from the baseline urinary protein-to-creatinine ratio at week 13 was −47.6% (95% confidence interval, −60.0 to −31.3).”

Source: [Egbuna et al. (2023)](https://www.nejm.org/doi/full/10.1056/NEJMoa2202396)

<a id="topic-3.1.2.8.3-3"></a>

###### Time course of proteinuria reduction

> “The treatment response from baseline was rapid and approximately linear, with a decrease seen by day 15; proteinuria continued to decrease through week 13 (Figure 2B).”
> “Reduction in proteinuria was seen in both the nephrotic- and subnephrotic-range groups (mean change in the urinary protein-to-creatinine ratio, −47.7% and −47.5%, respectively) (Table 2) and was unrelated to background standard-care medications.”

Source: [Egbuna et al. (2023)](https://www.nejm.org/doi/full/10.1056/NEJMoa2202396)

<a id="topic-3.1.2.8.3-4"></a>

###### Analysis of all 16 participants regardless of adherence

> “In an analysis that included all 16 participants, regardless of adherence to inaxaplin treatment, the mean change in the urinary protein-to-creatinine ratio at week 13 was −44.0% (95% CI, −56.3 to −28.3); one participant did not have a reduction (Fig. S5).”
> “Although this participant had 100% adherence to treatment, there were no clinical characteristics that appeared to have influenced the lack of treatment response.”

Source: [Egbuna et al. (2023)](https://www.nejm.org/doi/full/10.1056/NEJMoa2202396)

<a id="topic-3.1.2.8.3-5"></a>

###### Part B: UPCR after stopping inaxaplin

> “As compared with the baseline reduction in proteinuria that was observed at the end of part A of the study, in the exploratory part B of the study (in which data from nine participants were assessed), the mean urinary protein-to-creatinine ratio increased from −47.6% to −30.1% at week 4. The urinary protein-to-creatinine ratio remained stable for an additional 8 weeks (Fig. S6).”

Source: [Egbuna et al. (2023)](https://www.nejm.org/doi/full/10.1056/NEJMoa2202396)

<a id="topic-3.1.2.8.3-6"></a>

###### Pharmacokinetics: AUC0-24h at week 5 (secondary outcome)

| Measure | Quoted record |
| --- | --- |
| Outcome measure | “Area Under the Concentration Time-curve From 0 to 24 Hours (AUC0-24hr) of VX-147” |
| Time frame | “Pre-dose and at 0.25, 0.5, 1, 2, 4, 12 and 24 hours Post-dose on Week 5” |
| Overall number of participants analyzed | “13” |
| Mean (standard deviation), h*mcg/mL | “15.3(6.37)” |

Source: [ClinicalTrials.gov NCT04340362 results](https://clinicaltrials.gov/study/NCT04340362?tab=results)

<a id="topic-3.1.2.8.3-7"></a>

###### Company statement of the primary endpoint result

> “In the 13 evaluable patients, treatment with VX-147 on top of standard of care resulted in a rapid, statistically significant and clinically meaningful mean change in proteinuria from baseline of -47.6% (95% CI: -60.0%, -31.3%) following 13 weeks of treatment.”
> “Results were consistent regardless of baseline proteinuria or background therapy.”

Source: [Vertex Pharmaceuticals press release, phase 2 results (2021)](https://news.vrtx.com/news-releases/news-release-details/vertex-announces-positive-results-phase-2-study-vx-147-apol1)

<a id="heading-3.1.2.8.4"></a>

###### 3.1.2.8.4 Health-related Quality of Life and Patient-reported Outcomes

<a id="topic-3.1.2.8.4-1"></a>

###### SF-36 planned as an exploratory endpoint

> “Change from baseline in patient-reported outcome (PRO) Short Form Health Survey 36 (SF-36) over time during the Treatment Period”
> “Change in SF-36 from baseline over the study treatment period will be assessed as an exploratory outcome. SF-36 is a patient-reported generic measure of health status.”

Source: [Vertex Pharmaceuticals VX19-147-101 protocol (2021)](https://cdn.clinicaltrials.gov/large-docs/62/NCT04340362/Prot_000.pdf)

<a id="topic-3.1.2.8.4-2"></a>

###### SF-36 results

No evidence found.

<a id="heading-3.1.2.8.5"></a>

###### 3.1.2.8.5 Safety Results

<a id="topic-3.1.2.8.5-1"></a>

###### Overview of adverse events

> “Among the 16 participants who received at least one dose of inaxaplin, 15 (94%) had at least one adverse event. All the adverse events were mild or moderate in severity; there were no treatment discontinuations due to adverse events. Adverse events that occurred in more than 2 participants were headache, back pain, and nausea (Table 3).”
> “Three participants had adverse events that were considered by the investigator to be possibly related to inaxaplin (2 participants with headache and 1 participant with headache, abdominal distension, dyspepsia, and back pain).”
> “Two serious adverse events occurred in 1 participant: deep-vein thrombosis and uterine leiomyoma; neither event was considered by the investigator to be related to inaxaplin.”

Source: [Egbuna et al. (2023)](https://www.nejm.org/doi/full/10.1056/NEJMoa2202396)

<a id="topic-3.1.2.8.5-2"></a>

###### Adverse events (Table 3)

| Event, no. (%) | Total (N=16) | Nephrotic-range proteinuria (N=3) | Subnephrotic-range proteinuria (N=13) |
| --- | --- | --- | --- |
| Any adverse event | “15 (94)” | “3 (100)” | “12 (92)” |
| Mild | “7 (44)” | “1 (33)” | “6 (46)” |
| Moderate | “8 (50)” | “2 (67)” | “6 (46)” |
| Serious adverse event | “1 (6)” | “0” | “1 (8)” |
| Headache | “4 (25)” | “1 (33)” | “3 (23)” |
| Back pain | “3 (19)” | “0” | “3 (23)” |
| Nausea | “3 (19)” | “1 (33)” | “2 (15)” |
| Decrease in blood bicarbonate level | “2 (12)” | “0” | “2 (15)” |
| Diarrhea | “2 (12)” | “1 (33)” | “1 (8)” |
| Dizziness | “2 (12)” | “0” | “2 (15)” |
| Dyspepsia | “2 (12)” | “0” | “2 (15)” |
| Fatigue | “2 (12)” | “0” | “2 (15)” |

Source: [Egbuna et al. (2023)](https://www.nejm.org/doi/full/10.1056/NEJMoa2202396)

<a id="topic-3.1.2.8.5-3"></a>

###### Laboratory values, electrocardiograms, vital signs, and eGFR

> “There were no clinically significant safety findings in other clinical or laboratory assessments, including the hemoglobin level, liver-enzyme levels, total bilirubin level, lipid concentrations, electrocardiograms, or vital signs. Participants had a stable estimated GFR and blood pressure throughout the study (Fig. S7 and Table S4).”

Source: [Egbuna et al. (2023)](https://www.nejm.org/doi/full/10.1056/NEJMoa2202396)

<a id="topic-3.1.2.8.5-4"></a>

###### Deaths, serious adverse events, and other adverse events in the posted results

| Measure, affected / at risk (%) | Cohort 1 | Cohort 2 | Total |
| --- | --- | --- | --- |
| All-cause mortality | “0/3 (0.00%)” | “0/13 (0.00%)” | “0/16 (0.00%)” |
| Serious adverse events, total | “0/3 (0.00%)” | “1/13 (7.69%)” | “1/16 (6.25%)” |
| Other (not including serious) adverse events, total | “3/3 (100.00%)” | “12/13 (92.31%)” | “15/16 (93.75%)” |

Source: [ClinicalTrials.gov NCT04340362 results](https://clinicaltrials.gov/study/NCT04340362?tab=results)

<a id="topic-3.1.2.8.5-5"></a>

###### Adverse events in investigations and cardiac disorders in the posted results

| Event | Total, affected / at risk (%) |
| --- | --- |
| Blood bicarbonate decreased | “2/16 (12.50%)” |
| Blood creatine phosphokinase increased | “1/16 (6.25%)” |
| Electrocardiogram ST segment depression | “1/16 (6.25%)” |
| Gamma-glutamyltransferase increased | “1/16 (6.25%)” |
| Transaminases increased | “1/16 (6.25%)” |
| Palpitations | “1/16 (6.25%)” |

Source: [ClinicalTrials.gov NCT04340362 results](https://clinicaltrials.gov/study/NCT04340362?tab=results)

<a id="topic-3.1.2.8.5-6"></a>

###### Company statement on safety

> “There were no treatment discontinuations due to adverse events (AEs), and there were no serious adverse events considered related to study drug. All AEs were mild or moderate in severity. The most common AEs (occurring in > 15% of subjects) were headache, back pain and nausea.”

Source: [Vertex Pharmaceuticals press release, phase 2 results (2021)](https://news.vrtx.com/news-releases/news-release-details/vertex-announces-positive-results-phase-2-study-vx-147-apol1)

<a id="heading-3.1.2.9"></a>

##### 3.1.2.9 Study Limitations

<a id="topic-3.1.2.9-1"></a>

###### Summary: study limitations

VX19-147-101 was a single-group, open-label study without a placebo group; the protocol states that a placebo arm was omitted because of a “very low likelihood of spontaneous remission”. Sixteen participants were enrolled, and the primary analysis included the 13 participants with at least 80% adherence; the planned sample size of 10 was chosen for the precision of the geometric mean estimate, without a power calculation. Treatment lasted 13 weeks, and the off-treatment follow-up (part B) included 9 participants. The primary endpoint was the percent change from baseline in the urinary protein-to-creatinine ratio at week 13, and the secondary endpoints were safety and pharmacokinetics. Eligibility required biopsy-proven focal segmental glomerulosclerosis, two APOL1 variants, age 18 to 65 years, and an estimated GFR of at least 30 mL/min/1.73 m2 (±10%), so other APOL1-mediated kidney disease phenotypes were not studied; only 3 participants had nephrotic-range proteinuria. All 16 participants were Black or African American and were enrolled at sites in France, the United Kingdom, and the United States. The protocol listed SF-36 as an exploratory endpoint, and no SF-36 results were located in the published report or the posted results.

Source: [Egbuna et al. (2023)](https://www.nejm.org/doi/full/10.1056/NEJMoa2202396); [Vertex Pharmaceuticals VX19-147-101 protocol (2021)](https://cdn.clinicaltrials.gov/large-docs/62/NCT04340362/Prot_000.pdf); [ClinicalTrials.gov NCT04340362 results](https://clinicaltrials.gov/study/NCT04340362?tab=results)

<a id="topic-3.1.2.9-2"></a>

###### Limitations stated by the investigators

> “Our study has certain limitations. It was small, short in duration, and not placebo-controlled.”
> “Although only three participants with nephrotic-range proteinuria were enrolled in this study, the results in these participants appeared to be consistent with those observed in participants who had less-severe proteinuria.”

Source: [Egbuna et al. (2023)](https://www.nejm.org/doi/full/10.1056/NEJMoa2202396)

<a id="topic-3.1.2.9-3"></a>

###### Other APOL1-mediated kidney disease phenotypes not studied

> “The effects of inaxaplin therapy in this short-term clinical study involving participants with two APOL1 variants and biopsy-proven focal segmental glomerulosclerosis (a severe, rapidly progressive form of proteinuric CKD) remain to be studied in persons with two APOL1 variants and other types of proteinuric CKD, such as hypertensive kidney disease.”

Source: [Egbuna et al. (2023)](https://www.nejm.org/doi/full/10.1056/NEJMoa2202396)

<a id="topic-3.1.2.9-4"></a>

###### Commentary: lack of randomization, population, and endpoint

> “First, this is not a randomized control trial, there is therefore a need for a phase 3 clinical trial of inaxaplin + standard of care versus placebo + standard of care before clinical use.”
> “Second, the study was carried out in a small population of participants from Europe and North America.”
> “This point is especially important since Africans living in Africa were not part of this study.”
> “Third, reduction in proteinuria was used as the primary end point for this study”

Source: [Gbadegesin et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10461697/)

Additional sources: [Williams and Ingelfinger (2023)](https://pubmed.ncbi.nlm.nih.gov/36920762/); [Soler et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37379147/)

<a id="heading-3.1.3"></a>

#### 3.1.3 AMPLIFIED

<a id="heading-3.1.3.1"></a>

##### 3.1.3.1 Objective

<a id="topic-3.1.3.1-1"></a>

###### Purpose stated in the ClinicalTrials.gov brief summary

> “The purpose of the study is to evaluate the efficacy, safety, and tolerability of Inaxaplin (IXP) in participants with proteinuric APOL1- mediated kidney disease (AMKD).”

Source: [ClinicalTrials.gov NCT06794996](https://clinicaltrials.gov/study/NCT06794996)

<a id="topic-3.1.3.1-2"></a>

###### Aim stated in the design abstract

> “Given the potential of IXP to treat AMKD, it is essential to assess its efficacy in a broader population, including many of whom have comorbidities that may independently contribute to chronic kidney disease and accelerate disease progression.”
> “Here we describe the design of the proof-of-concept AMPLIFIED study evaluating IXP in persons with AMKD with mild to moderate proteinuria and no comorbidities and people with AMKD with mild to severe proteinuria and significant comorbidities that may worsen kidney dysfunction.”
> “The AMPLIFIED study will provide safety and efficacy data on the potential for IXP to treat a diverse population of AMKD patients with concurrent significant comorbidities associated with proteinuric kidney disease.”

Source: [Chertow et al. (2025b)](https://www.ovid.com/jnls/jasn/fulltext/10.1681/asn.20252q319dky~inaxaplin-for-a-broad-population-with-apol1-mediated-kidney)

<a id="topic-3.1.3.1-3"></a>

###### Populations outside the pivotal trial stated by the company

> “AMPLIFIED is a Phase 2, single-arm, open-label study evaluating the effect of treatment with a 45 mg once-daily dose of inaxaplin for 13 weeks to reduce proteinuria in people with AMKD with modest proteinuria, and people with AMKD and type 2 diabetes — populations not being studied in the AMPLITUDE trial.”

Source: [Vertex Pharmaceuticals press release, AMPLIFIED results (2026)](https://news.vrtx.com/news-releases/news-release-details/vertex-announces-positive-results-phase-2b-amplified-study)

<a id="topic-3.1.3.1-4"></a>

###### Indication expansion stated in the annual report

> “Our serial innovation strategy in AMKD focuses on indication expansion: evaluating inaxaplin in new populations of people with AMKD not included in the AMPLITUDE clinical trial.”

Source: [Vertex Pharmaceuticals Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/875320/000087532026000056/vrtx-20251231.htm)

<a id="topic-3.1.3.1-5"></a>

###### Planned study announced by the company

> “Vertex plans to initiate AMPLIFIED, a Phase 2b open-label study of inaxaplin in patients with AMKD and diabetes or other co-morbidities currently not eligible for the AMPLITUDE Phase 2/3 pivotal trial, expanding the estimated potentially eligible population from 150,000 to 250,000 patients.”

Source: [Vertex Pharmaceuticals press release, pipeline and business updates (2025)](https://news.vrtx.com/news-releases/news-release-details/vertex-provides-pipeline-and-business-updates-advance-upcoming-0)

<a id="heading-3.1.3.2"></a>

##### 3.1.3.2 Location and Study Date

<a id="topic-3.1.3.2-1"></a>

###### Study dates and status in the ClinicalTrials.gov record

> “Study Start (Actual) 2025-02-04”
> “Primary Completion (Actual) 2026-07-20”
> “Study Completion (Actual) 2026-07-20”
> “First Posted 2025-01-27”
> “Last Update Posted 2026-08-20”
> “Completed”
> “No Results Posted”

Source: [ClinicalTrials.gov NCT06794996](https://clinicaltrials.gov/study/NCT06794996)

<a id="topic-3.1.3.2-2"></a>

###### Number of locations in the ClinicalTrials.gov record

> “This study has 35 locations”

Source: [ClinicalTrials.gov NCT06794996](https://clinicaltrials.gov/study/NCT06794996)

<a id="topic-3.1.3.2-3"></a>

###### Study locations by state in the ClinicalTrials.gov record

| State | Locations listed in the record |
| --- | --- |
| Alabama | “Huntsville, Alabama, United States, 35805” |
| Florida | “Hollywood, Florida, United States, 33023”; “Lauderdale Lakes, Florida, United States, 33313”; “Miami, Florida, United States, 33136”; “Orlando, Florida, United States, 32806” |
| Georgia | “Columbus, Georgia, United States, 31904”; “Decatur, Georgia, United States, 30030”; “Fayetteville, Georgia, United States, 30214”; “Lawrenceville, Georgia, United States, 30046”; “Savannah, Georgia, United States, 31406” |
| Louisiana | “Baton Rouge, Louisiana, United States, 70808”; “Metairie, Louisiana, United States, 70006”; “New Orleans, Louisiana, United States, 70121”; “Shreveport, Louisiana, United States, 71101” |
| Maryland | “Silver Spring, Maryland, United States, 20901” |
| Mississippi | “Columbus, Mississippi, United States, 39705”; “Tupelo, Mississippi, United States, 38801” |
| Nevada | “Las Vegas, Nevada, United States, 89107” |
| New Jersey | “Newark, New Jersey, United States, 07102”; “Newark, New Jersey, United States, 07103” |
| New York | “Laurelton, New York, United States, 11413”; “New York, New York, United States, 10037” |
| North Carolina | “Cary, North Carolina, United States, 27511”; “Chapel Hill, North Carolina, United States, 27599-7155”; “Durham, North Carolina, United States, 27710”; “New Bern, North Carolina, United States, 28562” |
| Pennsylvania | “Philadelphia, Pennsylvania, United States, 19140” |
| South Carolina | “Columbia, South Carolina, United States, 29203”; “Spartanburg, South Carolina, United States, 29306” |
| Texas | “Dallas, Texas, United States, 75230”; “Dallas, Texas, United States, 75237”; “Dallas, Texas, United States, 75246”; “Dallas, Texas, United States, 75390”; “Houston, Texas, United States, 77054” |
| Virginia | “Norfolk, Virginia, United States, 23504” |

Source: [ClinicalTrials.gov NCT06794996](https://clinicaltrials.gov/study/NCT06794996)

<a id="topic-3.1.3.2-4"></a>

###### Completion of enrollment reported in the first quarter 2026 results

> “Vertex has completed enrollment in the AMPLIFIED Phase 2 study of inaxaplin.”

Source: [Vertex Pharmaceuticals first quarter 2026 results (2026)](https://www.sec.gov/Archives/edgar/data/875320/000087532026000171/ex-991_q12026.htm)

<a id="topic-3.1.3.2-5"></a>

###### Completion of enrollment and dosing reported in the second quarter 2026 results

> “Vertex has completed enrollment and dosing in the AMPLIFIED Phase 2 study of inaxaplin and is on track to share data this fall.”

Source: [Vertex Pharmaceuticals second quarter 2026 results (2026)](https://www.sec.gov/Archives/edgar/data/875320/000087532026000256/ex-991_q22026.htm)

<a id="topic-3.1.3.2-6"></a>

###### Date of the results announcement

> “BOSTON--(BUSINESS WIRE)--Sep. 22, 2026-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced positive results from the Phase 2b AMPLIFIED study of inaxaplin in people with APOL1-mediated kidney disease (AMKD) and modest proteinuria and in people with AMKD and type 2 diabetes.”

Source: [Vertex Pharmaceuticals press release, AMPLIFIED results (2026)](https://news.vrtx.com/news-releases/news-release-details/vertex-announces-positive-results-phase-2b-amplified-study)

<a id="heading-3.1.3.3"></a>

##### 3.1.3.3 Study Design

<a id="topic-3.1.3.3-1"></a>

###### Official title in the ClinicalTrials.gov record

> “A Phase 2b, Open-label Study to Evaluate the Efficacy and Safety of Inaxaplin in Subjects With Proteinuric APOL1-mediated Kidney Disease With or Without Comorbidities That May Independently Contribute to Chronic Kidney Disease”

Source: [ClinicalTrials.gov NCT06794996](https://clinicaltrials.gov/study/NCT06794996)

<a id="topic-3.1.3.3-2"></a>

###### Design details in the ClinicalTrials.gov record

| Field | Registry value |
| --- | --- |
| Study type | “Interventional” |
| Phase | “Phase 2” |
| Primary purpose | “Treatment” |
| Allocation | “N/A” |
| Interventional model | “Single Group Assignment” |
| Masking | “None (Open Label)” |

Source: [ClinicalTrials.gov NCT06794996](https://clinicaltrials.gov/study/NCT06794996)

<a id="topic-3.1.3.3-3"></a>

###### Planned cohorts in the design abstract

> “AMPLIFIED is a phase 2, open-label study evaluating the efficacy of IXP to reduce proteinuria in 45 participants (ages 18-67yrs) with proteinuric AMKD who have none (Cohort 1,n=15) or one of the following significant comorbidities: type 2 diabetes mellitus (Cohort 2,n=15), sickle-cell disease (Cohort 3,n=5), human immunodeficiency virus (Cohort 3,n=5), or lupus nephritis (Cohort 3,n=5).”

Source: [Chertow et al. (2025b)](https://www.ovid.com/jnls/jasn/fulltext/10.1681/asn.20252q319dky~inaxaplin-for-a-broad-population-with-apol1-mediated-kidney)

<a id="topic-3.1.3.3-4"></a>

###### Single-arm, open-label design with two reported cohorts

> “AMPLIFIED is a Phase 2, single-arm, open-label study evaluating the effect of treatment with a 45 mg once-daily dose of inaxaplin for 13 weeks to reduce proteinuria in people with AMKD with modest proteinuria, and people with AMKD and type 2 diabetes”
> “Forty-one people were enrolled and dosed in two cohorts”

Source: [Vertex Pharmaceuticals press release, AMPLIFIED results (2026)](https://news.vrtx.com/news-releases/news-release-details/vertex-announces-positive-results-phase-2b-amplified-study)

<a id="heading-3.1.3.4"></a>

##### 3.1.3.4 Eligibility Criteria

<a id="topic-3.1.3.4-1"></a>

###### Key inclusion and exclusion criteria in the ClinicalTrials.gov record

> “Participant has an APOL1 genotype of G1/G1, G2/G2, or G1/G2 obtained with a Vertex designated investigational clinical study assay”
> “Estimated Glomerular Filtration Rate (eGFR) of greater than or equal to (≥) 25 milliliter per minute (mL/min)/1.73m^2 at screening”
> “Evidence of Focal Segmental Glomerulosclerosis (FSGS) with a known cause other than due to APOL1 risk variants”
> “Uncontrolled hypertension”
> “Other protocol defined Inclusion/Exclusion criteria may apply.”

Source: [ClinicalTrials.gov NCT06794996](https://clinicaltrials.gov/study/NCT06794996)

<a id="topic-3.1.3.4-2"></a>

###### Age, sex, and healthy volunteers in the ClinicalTrials.gov record

| Field | Registry value |
| --- | --- |
| Ages eligible for study | “18 Years to 67 Years” |
| Sexes eligible for study | “All” |
| Accepts healthy volunteers | “No” |

Source: [ClinicalTrials.gov NCT06794996](https://clinicaltrials.gov/study/NCT06794996)

<a id="topic-3.1.3.4-3"></a>

###### Proteinuria thresholds by cohort in the design abstract

> “Participants in Cohort 1 have mild to moderate proteinuria defined as urine albumin-creatinine ratio (UACR) ≥100mg/g to <420mg/g and participants in Cohorts 2 and 3 have mild to severe proteinuria defined as UACR ≥100mg/g to <6000mg/g.”

Source: [Chertow et al. (2025b)](https://www.ovid.com/jnls/jasn/fulltext/10.1681/asn.20252q319dky~inaxaplin-for-a-broad-population-with-apol1-mediated-kidney)

<a id="topic-3.1.3.4-4"></a>

###### Proteinuria thresholds by cohort stated with the results

> “1) people with AMKD with modest proteinuria (UACR ≥0.1 g/g to <0.42 g/g) were eligible for cohort 1 (N=23), and 2) people with AMKD, type 2 diabetes and proteinuria (UACR ≥0.1 g/g to <6 g/g) were eligible for cohort 2 (N=18).”

Source: [Vertex Pharmaceuticals press release, AMPLIFIED results (2026)](https://news.vrtx.com/news-releases/news-release-details/vertex-announces-positive-results-phase-2b-amplified-study)

<a id="topic-3.1.3.4-5"></a>

###### Pivotal trial population that AMPLIFIED excludes

> “Vertex has completed full enrollment in the Phase 2/3 AMPLITUDE study of inaxaplin in people with severe proteinuria and no other kidney disease-causing comorbidities.”

Source: [Vertex Pharmaceuticals press release, AMPLIFIED results (2026)](https://news.vrtx.com/news-releases/news-release-details/vertex-announces-positive-results-phase-2b-amplified-study)

<a id="heading-3.1.3.5"></a>

##### 3.1.3.5 Treatment

<a id="topic-3.1.3.5-1"></a>

###### Arm and intervention in the ClinicalTrials.gov record

> “Experimental: IXP (Inaxaplin)”
> “Participants with proteinuric APOL1-mediated kidney disease (AMKD) with or without the comorbidity of Type 2 diabetes mellitus (T2DM) will receive a single dose of IXP once daily, for 13 weeks.”
> “Tablets for Oral Administration.”

Source: [ClinicalTrials.gov NCT06794996](https://clinicaltrials.gov/study/NCT06794996)

<a id="topic-3.1.3.5-2"></a>

###### Dose and background therapy stated with the results

> “In this study, inaxaplin was evaluated as a 45 mg once-daily dose on top of optimized standard of care.”

Source: [Vertex Pharmaceuticals press release, AMPLIFIED results (2026)](https://news.vrtx.com/news-releases/news-release-details/vertex-announces-positive-results-phase-2b-amplified-study)

<a id="heading-3.1.3.6"></a>

##### 3.1.3.6 Study Outcomes

<a id="heading-3.1.3.6.1"></a>

###### 3.1.3.6.1 Rationale for Using Percent Change in UACR as the Primary Endpoint

<a id="topic-3.1.3.6.1-1"></a>

###### Registered primary and secondary outcome measures in the ClinicalTrials.gov record

| Role | Outcome measure | Time frame |
| --- | --- | --- |
| Primary | “Percent Change in Urine Albumin-Creatinine Ratio (UACR)” | “Baseline and At Week 13” |
| Secondary | “Safety and Tolerability as Assessed by Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)” | “From Baseline Up To Week 17” |

Source: [ClinicalTrials.gov NCT06794996](https://clinicaltrials.gov/study/NCT06794996)

<a id="topic-3.1.3.6.1-2"></a>

###### Primary and other endpoints stated with the results

> “The primary endpoint in the study was mean percent change in UACR at Week 13 compared to baseline, evaluated separately for each cohort. The other endpoints included mean percent change in urine protein to creatinine ratio (UPCR) at Week 13 compared to baseline and safety.”

Source: [Vertex Pharmaceuticals press release, AMPLIFIED results (2026)](https://news.vrtx.com/news-releases/news-release-details/vertex-announces-positive-results-phase-2b-amplified-study)

<a id="topic-3.1.3.6.1-3"></a>

###### Planned endpoints in the design abstract

> “The primary efficacy endpoint will be the percent change from baseline in proteinuria at week 13. Safety will be evaluated.”

Source: [Chertow et al. (2025b)](https://www.ovid.com/jnls/jasn/fulltext/10.1681/asn.20252q319dky~inaxaplin-for-a-broad-population-with-apol1-mediated-kidney)

<a id="topic-3.1.3.6.1-4"></a>

###### Albuminuria change as a surrogate endpoint across 48 randomized trials

> “Here, in an individual participant data analysis of 48 randomized controlled trials (studies) involving 85,681 participants, we assessed the association between treatment effects on 6-month urinary albumin:creatinine ratio (UACR) change and the established clinical endpoint of kidney failure or doubling of serum creatinine concentrations.”
> “Across all trials, each 30% reduction in the geometric mean of the UACR in the treatment group relative to the control group was associated with an average of 19% lower hazard for the clinical endpoint (95% Bayesian credible interval (BCI): 5-30%); median coefficient of determination (R2) = 0.66 (95% BCI: 0.06-0.98).”
> “There was no clear evidence that this association varied by CKD etiology.”

Source: [Heerspink et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/41198855/)

<a id="topic-3.1.3.6.1-5"></a>

###### Albuminuria change and kidney outcomes in APOL1-mediated kidney disease

> “Recently, proteinuria has been accepted as a surrogate end point for clinical trials in focal segmental glomerulosclerosis (FSGS) ang IgA nephropathy. However, proteinuria has not been evaluated in Apolipoprotein L1 (APOL1)-mediated kidney disease (AMKD).”
> “Real world data (RWD) analysis of 128 patients of African ancestry with APOL1 high risk genotypes, without diabetes, enrolled in the Million Veteran Program (MVP; n=109) or the biorepository at Vanderbilt University (BioVU; n=19), who had urine albumin-creatinine ratio (UACR) >= 420 mg/g (PCR~0.9 g/g) with a concurrent GFR value.”
> “It was estimated that a 50% reduction of UACR at 12 months was associated with a 28% reduction in the kidney composite endpoint (adjusted hazard ratio [aHR]=0.72; 95% confidence interval [CI]:0.59−0.88; p=0.002), and a 38% reduction in the risk of ESKD (aHR=0.62; 95% CI:0.49−0.80; p<0.001).”
> “Changes in UACR at 12 months significantly modify the rate of decline of GFR over 24 months and clinically meaningful endpoints, supporting the use of UACR changes as surrogate endpoint in AMKD.”

Source: [Mamak et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13278290/)

<a id="topic-3.1.3.6.1-6"></a>

###### Conditions under which albuminuria reduction is considered a reasonably likely surrogate

> “It was considered that changes in albuminuria may be informative when baseline albuminuria is large and has a dominant role in disease progression and the therapeutic under investigation has a mechanistic relationship to reduce albuminuria.”

Source: [Mamak et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13278290/)

<a id="topic-3.1.3.6.1-7"></a>

###### Comparison with the phase 2a result stated by the company

> “These results are in line with the treatment effect previously reported in the Phase 2a study of inaxaplin in AMKD with focal segmental glomerulosclerosis (FSGS), which demonstrated a reduction in UACR of -43.4% and a reduction in UPCR of -47.6% at Week 13 compared to baseline.”

Source: [Vertex Pharmaceuticals press release, AMPLIFIED results (2026)](https://news.vrtx.com/news-releases/news-release-details/vertex-announces-positive-results-phase-2b-amplified-study)

<a id="heading-3.1.3.7"></a>

##### 3.1.3.7 Statistical Analysis Description

<a id="heading-3.1.3.7.1"></a>

###### 3.1.3.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.3.7.1-1"></a>

###### Planned enrollment in the design abstract

> “AMPLIFIED is a phase 2, open-label study evaluating the efficacy of IXP to reduce proteinuria in 45 participants (ages 18-67yrs)”

Source: [Chertow et al. (2025b)](https://www.ovid.com/jnls/jasn/fulltext/10.1681/asn.20252q319dky~inaxaplin-for-a-broad-population-with-apol1-mediated-kidney)

<a id="topic-3.1.3.7.1-2"></a>

###### Actual enrollment in the ClinicalTrials.gov record

> “Enrollment (Actual) 42”

Source: [ClinicalTrials.gov NCT06794996](https://clinicaltrials.gov/study/NCT06794996)

<a id="topic-3.1.3.7.1-3"></a>

###### Participants dosed and analyzed by cohort stated with the results

| Cohort | Enrolled and dosed | Efficacy analysis | On treatment with a week 13 assessment |
| --- | --- | --- | --- |
| Cohort 1: AMKD with modest proteinuria | “N=23” | “N=22” | “18 and 14 people in cohort 1 and 2, respectively” |
| Cohort 2: AMKD with type 2 diabetes | “N=18” | “N=17” | “18 and 14 people in cohort 1 and 2, respectively” |

Source: [Vertex Pharmaceuticals press release, AMPLIFIED results (2026)](https://news.vrtx.com/news-releases/news-release-details/vertex-announces-positive-results-phase-2b-amplified-study)

<a id="heading-3.1.3.7.2"></a>

###### 3.1.3.7.2 Description of Analysis Sets

<a id="topic-3.1.3.7.2-1"></a>

###### Efficacy analysis set and week 13 analysis population

> “According to the pre-specified statistical analysis plan, two people, one in each cohort, who were noncompliant with treatment, were not included in the efficacy analyses.”
> “Analyses include those on treatment who had an assessment at Week 13: 18 and 14 people in cohort 1 and 2, respectively.”

Source: [Vertex Pharmaceuticals press release, AMPLIFIED results (2026)](https://news.vrtx.com/news-releases/news-release-details/vertex-announces-positive-results-phase-2b-amplified-study)

<a id="topic-3.1.3.7.2-2"></a>

###### Geometric mean percent change by cohort and post hoc confidence intervals

> “The primary endpoint in the study was mean percent change in UACR at Week 13 compared to baseline, evaluated separately for each cohort.”
> “Mean % change (geometric) of UACR at Week 13 compared to baseline”
> “95% CI were generated post-hoc”

Source: [Vertex Pharmaceuticals press release, AMPLIFIED results (2026)](https://news.vrtx.com/news-releases/news-release-details/vertex-announces-positive-results-phase-2b-amplified-study)

<a id="heading-3.1.3.8"></a>

##### 3.1.3.8 Results

<a id="heading-3.1.3.8.1"></a>

###### 3.1.3.8.1 Participant Disposition

<a id="topic-3.1.3.8.1-1"></a>

###### Participants enrolled, dosed, and excluded from the efficacy analyses

> “Forty-one people were enrolled and dosed in two cohorts”
> “According to the pre-specified statistical analysis plan, two people, one in each cohort, who were noncompliant with treatment, were not included in the efficacy analyses.”

Source: [Vertex Pharmaceuticals press release, AMPLIFIED results (2026)](https://news.vrtx.com/news-releases/news-release-details/vertex-announces-positive-results-phase-2b-amplified-study)

<a id="heading-3.1.3.8.2"></a>

###### 3.1.3.8.2 Baseline Characteristics

<a id="topic-3.1.3.8.2-1"></a>

###### Baseline UACR and UPCR by cohort

| Measure | Cohort 1: AMKD with modest proteinuria | Cohort 2: AMKD with type 2 diabetes |
| --- | --- | --- |
| Mean baseline UACR g/g (standard deviation) | “0.28 (0.09)” | “0.67 (0.87)” |
| Mean baseline UPCR g/g (standard deviation) | “0.46 (0.20)” | “1.12 (1.51)” |

Source: [Vertex Pharmaceuticals press release, AMPLIFIED results (2026)](https://news.vrtx.com/news-releases/news-release-details/vertex-announces-positive-results-phase-2b-amplified-study)

<a id="topic-3.1.3.8.2-2"></a>

###### FSGS diagnosis and background kidney therapy

> “In this modest proteinuria cohort, most people were not diagnosed with FSGS.”
> “These patients were already well treated with foundational chronic kidney disease therapies and treatment with inaxaplin led to additional reductions in proteinuria.”

Source: [Vertex Pharmaceuticals press release, AMPLIFIED results (2026)](https://news.vrtx.com/news-releases/news-release-details/vertex-announces-positive-results-phase-2b-amplified-study)

<a id="topic-3.1.3.8.2-3"></a>

###### FSGS diagnosis in both cohorts stated on the earnings call

> “Of note, the majority of patients in both cohorts did not have a diagnosis of FSGS.”
> “The majority of patients did not have FSGS. So they did not have a biopsy, and they did not have FSGS, which you would expect because their proteinuria is modest and you are correct.”

Source: [Vertex Pharmaceuticals earnings call transcript (2026)](https://www.webull.com/news/15858478693325824)

<a id="heading-3.1.3.8.3"></a>

###### 3.1.3.8.3 Efficacy Results

<a id="topic-3.1.3.8.3-1"></a>

###### Percent change in UACR and UPCR at week 13 by cohort

| Endpoint | Cohort 1: AMKD with modest proteinuria | Cohort 2: AMKD with type 2 diabetes |
| --- | --- | --- |
| Primary: geometric mean percent change in UACR at week 13 (95% confidence interval) | “-42.7%”; “(-58.3%, -21.1%)” | “-17.3%”; “(-36.3%, 7.2%)” |
| Other: geometric mean percent change in UPCR at week 13 (95% confidence interval) | “-44.7%”; “(-60.9%, -21.9%)” | “-25.4%”; “(-45.1%, 1.4%)” |

Source: [Vertex Pharmaceuticals press release, AMPLIFIED results (2026)](https://news.vrtx.com/news-releases/news-release-details/vertex-announces-positive-results-phase-2b-amplified-study)

<a id="topic-3.1.3.8.3-2"></a>

###### Cohort 1: AMKD with modest proteinuria

> “In cohort 1, treatment with inaxaplin administered on top of optimized standard of care led to a reduction of -42.7% (95% CI -58.3%, -21.1%) in UACR at Week 13 compared to baseline. UPCR decreased by -44.7% from baseline at Week 13.”

Source: [Vertex Pharmaceuticals press release, AMPLIFIED results (2026)](https://news.vrtx.com/news-releases/news-release-details/vertex-announces-positive-results-phase-2b-amplified-study)

<a id="topic-3.1.3.8.3-3"></a>

###### Cohort 2: AMKD with type 2 diabetes

> “In cohort 2, treatment with inaxaplin administered on top of optimized standard of care led to a reduction in UACR at Week 13 of -17.3% (95% CI -36.3%, 7.2%) compared to baseline. UPCR decreased by -25.4% from baseline at Week 13.”

Source: [Vertex Pharmaceuticals press release, AMPLIFIED results (2026)](https://news.vrtx.com/news-releases/news-release-details/vertex-announces-positive-results-phase-2b-amplified-study)

<a id="topic-3.1.3.8.3-4"></a>

###### Results restated in the third quarter 2026 results

> “Vertex announced positive results from the Phase 2b AMPLIFIED study of inaxaplin in people with AMKD with modest proteinuria (improvement in urine albumin to creatinine ratio [UACR] of -42.7%, and urine protein to creatinine ratio [UPCR] of -44.7%) and people with AMKD and Type 2 diabetes (improvement in UACR of -17.3%, UPCR of -25.4%)”

Source: [Vertex Pharmaceuticals third quarter 2026 results (2026)](https://www.sec.gov/Archives/edgar/data/875320/000087532026000287/ex-991_q32026.htm)

<a id="heading-3.1.3.8.4"></a>

###### 3.1.3.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.3.8.5"></a>

###### 3.1.3.8.5 Safety Results

<a id="topic-3.1.3.8.5-1"></a>

###### Serious adverse events, severity, headache, and transaminase elevations

> “Inaxaplin was generally safe and well tolerated across both cohorts. There were no serious adverse events (SAEs) related to inaxaplin. All adverse events (AEs) were mild or moderate in severity. The most common AE (occurring in >5% of subjects) was headache (7.3%). Five people had isolated, asymptomatic transaminase elevations, which resolved.”

Source: [Vertex Pharmaceuticals press release, AMPLIFIED results (2026)](https://news.vrtx.com/news-releases/news-release-details/vertex-announces-positive-results-phase-2b-amplified-study)

<a id="heading-3.1.3.9"></a>

##### 3.1.3.9 Study Limitations

<a id="topic-3.1.3.9-1"></a>

###### Summary: study limitations

AMPLIFIED was a single-arm, open-label study without a placebo or active comparator, so each cohort's result is a change from baseline over 13 weeks of inaxaplin 45 mg once daily added to “optimized standard of care”. Of 41 participants enrolled and dosed (23 in cohort 1 and 18 in cohort 2), 39 were in the efficacy analyses, and the week 13 analyses included 18 and 14 participants; the registry lists an actual enrollment of 42. The 95% confidence intervals “were generated post-hoc”, and in cohort 2 they include no change for both UACR (-36.3% to 7.2%) and UPCR (-45.1% to 1.4%). The design abstract planned 45 participants, including a third cohort of 15 participants with sickle cell disease, HIV, or lupus nephritis, which the results announcement does not report. The registry lists UACR as the only efficacy outcome measure, and UPCR is reported as an “other” endpoint. All 35 registered sites are in the United States, eligibility was limited to ages 18 to 67 years with eGFR of at least 25 mL/min/1.73 m2, and the only baseline characteristics reported are mean UACR and UPCR by cohort. The study measured no kidney function outcome. The AMKD-specific analysis supporting UACR change as a surrogate endpoint used 12-month changes in 128 participants without diabetes and with UACR of at least 420 mg/g, a range that excludes the cohort 1 eligibility range (UACR at least 100 to below 420 mg/g) and the cohort 2 population. As of 2026-11-15 the results are available only from company communications: the registry shows “No Results Posted”, and no peer-reviewed publication or congress presentation of the results was identified.

Source: [Vertex Pharmaceuticals press release, AMPLIFIED results (2026)](https://news.vrtx.com/news-releases/news-release-details/vertex-announces-positive-results-phase-2b-amplified-study); [ClinicalTrials.gov NCT06794996](https://clinicaltrials.gov/study/NCT06794996); [Chertow et al. (2025b)](https://www.ovid.com/jnls/jasn/fulltext/10.1681/asn.20252q319dky~inaxaplin-for-a-broad-population-with-apol1-mediated-kidney); [Mamak et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13278290/)

<a id="heading-3.1.4"></a>

#### 3.1.4 VX18-147-001

<a id="heading-3.1.4.1"></a>

##### 3.1.4.1 Objective

<a id="topic-3.1.4.1-1"></a>

###### Aims of the two phase 1 studies

> “We conducted two phase 1 studies evaluating the safety, tolerability, and pharmacokinetics of single-ascending doses (SAD) and multiple-ascending doses (MAD) of inaxaplin in healthy participants.”
> “Herein we report the safety, tolerability, and pharmacokinetics of inaxaplin from two phase 1 single-ascending dose (SAD)/multiple-ascending dose (MAD) studies in healthy participants.”

Source: [Egbuna et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11006409/)

<a id="topic-3.1.4.1-2"></a>

###### First-in-human study VX18-147-001

> “The first-in-human study of inaxaplin (Study VX18-147-001 or Study 1) evaluated single ascending doses of 7.5 mg up to 50 mg and multiple ascending doses of 15 mg once daily, 15 mg twice daily, or 45 mg once daily in healthy participants.”

Source: [Egbuna et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11006409/)

<a id="topic-3.1.4.1-3"></a>

###### Primary objective: safety and tolerability

> “The primary objective for Parts A and B of both phase 1 studies was to determine safety and tolerability based on assessment of adverse events (AEs), clinical laboratory assessments (serum chemistry, hematology, coagulation, and urinalysis), standard 12-lead ECG measures (performed in triplicate), and vital signs.”

Source: [Egbuna et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11006409/)

<a id="topic-3.1.4.1-4"></a>

###### CYP3A4 interaction objective in Study 1

> “We assessed the potential of inaxaplin to either induce or inhibit CYP3A4 enzymes in Study 1 by measuring the effect of inaxaplin administration on serum concentrations of midazolam, a sensitive CYP3A4 substrate.”

Source: [Egbuna et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11006409/)

<a id="heading-3.1.4.2"></a>

##### 3.1.4.2 Location and Study Date

<a id="topic-3.1.4.2-1"></a>

###### Sites and dates of Study 1

> “Study 1 was conducted at two sites in the United States (Madison, WI and Dallas, TX) between June 2019 and January 2020.”

Source: [Egbuna et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11006409/)

<a id="topic-3.1.4.2-2"></a>

###### Ethics approval

> “The study protocols were approved by the Advarra Institutional Review Board in the United States (Advarra IRB Identifiers: Pro00035356, Pro00034297, and Pro00044276).”

Source: [Egbuna et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11006409/)

<a id="heading-3.1.4.3"></a>

##### 3.1.4.3 Study Design

<a id="topic-3.1.4.3-1"></a>

###### Randomized, double-blind, placebo-controlled SAD/MAD design

> “We conducted two phase 1, randomized, double-blind, placebo-controlled SAD/MAD studies of inaxaplin in healthy participants.”

Source: [Egbuna et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11006409/)

<a id="topic-3.1.4.3-2"></a>

###### Part A single ascending doses and Part B multiple ascending doses

> “Part A of both phase 1 studies was designed to evaluate the safety and tolerability of single oral ascending doses of inaxaplin administered to healthy participants.”
> “Part B of both phase 1 studies was designed to evaluate the safety and tolerability of multiple oral ascending doses of inaxaplin administered to healthy participants.”

Source: [Egbuna et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11006409/)

<a id="topic-3.1.4.3-3"></a>

###### Unique participants per cohort and safety follow-up

> “All SAD and MAD cohorts included unique participants. There was no cross-over of participants within or across study cohorts. All participants had a Safety Follow-up Visit 7–10 days after the last dose of study drug.”

Source: [Egbuna et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11006409/)

<a id="topic-3.1.4.3-4"></a>

###### Sponsor design of the trials

> “These trials were designed by Vertex Pharmaceuticals.”

Source: [Egbuna et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11006409/)

<a id="heading-3.1.4.4"></a>

##### 3.1.4.4 Eligibility Criteria

<a id="topic-3.1.4.4-1"></a>

###### Healthy adults of non-childbearing potential

> “In both studies, we enrolled healthy men and women of non-childbearing potential who were at least 18 years of age with body weight of >50 kg and body mass index (BMI) 18.0 to 32.0 kg/m2.”
> “was defined by no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurement, standard 12-lead electrocardiogram (ECG), and clinical laboratory tests.”

Source: [Egbuna et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11006409/)

<a id="heading-3.1.4.5"></a>

##### 3.1.4.5 Treatment

<a id="topic-3.1.4.5-1"></a>

###### Single doses of 7.5 to 50 mg or placebo in Part A of Study 1

> “In Study 1, participants were randomized 3:1 to receive a single dose of inaxaplin (7.5 mg, 15 mg, 30 mg, 50 mg) or placebo.”

Source: [Egbuna et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11006409/)

<a id="topic-3.1.4.5-2"></a>

###### Multiple doses for 14 days or placebo in Part B of Study 1

> “In Study 1, participants were randomized 3:1 to receive multiple doses of inaxaplin (15 mg once daily, 15 mg twice daily, 45 mg once daily) or placebo for 14 days.”

Source: [Egbuna et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11006409/)

<a id="heading-3.1.4.6"></a>

##### 3.1.4.6 Study Outcomes

<a id="heading-3.1.4.6.1"></a>

###### 3.1.4.6.1 Rationale for Using Safety and Tolerability Assessments as the Primary Endpoints

<a id="topic-3.1.4.6.1-1"></a>

###### Primary safety and tolerability endpoints

> “The primary objective for Parts A and B of both phase 1 studies was to determine safety and tolerability based on assessment of adverse events (AEs), clinical laboratory assessments (serum chemistry, hematology, coagulation, and urinalysis), standard 12-lead ECG measures (performed in triplicate), and vital signs.”

Source: [Egbuna et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11006409/)

<a id="topic-3.1.4.6.1-2"></a>

###### Pharmacokinetic assessments

> “In both studies, we assessed plasma pharmacokinetic (PK) parameter estimates of inaxaplin (i.e., time of maximum concentration [tmax], maximum observed concentration [Cmax], area under the concentration vs. time curve from the time of dosing to 24 h [AUC0–24h], terminal phase half-life [t½], apparent volume of distribution [V/F], and apparent clearance at steady-state [CLss/F]) after multiple oral ascending doses of inaxaplin derived from plasma concentration-time data. We also assessed urine PK parameter estimates.”

Source: [Egbuna et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11006409/)

<a id="topic-3.1.4.6.1-3"></a>

###### Midazolam as a sensitive CYP3A4 substrate

> “We assessed the potential of inaxaplin to either induce or inhibit CYP3A4 enzymes in Study 1 by measuring the effect of inaxaplin administration on serum concentrations of midazolam, a sensitive CYP3A4 substrate.”

Source: [Egbuna et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11006409/)

<a id="heading-3.1.4.7"></a>

##### 3.1.4.7 Statistical Analysis Description

<a id="heading-3.1.4.7.1"></a>

###### 3.1.4.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.4.7.1-1"></a>

###### Participants randomized and dosed across both studies

> “One hundred and seventy eight participants were randomized and received at least one dose of study drug in the SAD and MAD cohorts of the two phase 1 studies.”
> “There were 21 participants who received placebo in the SAD cohort and 23 participants who received placebo in the MAD cohort.”
> “There were 63 participants who received inaxaplin in the SAD cohort and 71 participants who received inaxaplin in the MAD cohort.”

Source: [Egbuna et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11006409/)

<a id="topic-3.1.4.7.1-2"></a>

###### Participants per group in the MAD cohorts of Study 1

> “Inaxaplin 15 mg once daily (N = 9)”
> “Inaxaplin 15 mg twice daily (N = 9)”
> “Inaxaplin 45 mg once daily (N = 9)”
> “Placebo is pooled from all MAD cohorts in Study 1.”

Source: [Egbuna et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11006409/)

<a id="heading-3.1.4.7.2"></a>

###### 3.1.4.7.2 Description of Analysis Sets

<a id="topic-3.1.4.7.2-1"></a>

###### Safety set and descriptive analyses

> “N, Safety Set sample size”
> “This table includes all participants in the MAD cohorts of Study 1 who received at least one dose of study drug.”
> “In both phase 1 studies, we used descriptive analyses on safety data including AEs, clinical laboratory assessments, vital signs, and ECGs.”

Source: [Egbuna et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11006409/)

<a id="topic-3.1.4.7.2-2"></a>

###### Triplicate ECGs and pooled analysis across cohorts

> “Since ECGs were performed in triplicate, the mean of each individual ECG parameter measurement (i.e., PR, RR, QRS, QT, QTcF, heart rate) at each specific visit and time point was used as the ECG for that specific visit and time point for summary purposes. In addition to analyses performed in the SAD and MAD cohorts separately for the two studies, we conducted a pooled analysis across cohorts.”

Source: [Egbuna et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11006409/)

<a id="heading-3.1.4.8"></a>

##### 3.1.4.8 Results

<a id="heading-3.1.4.8.1"></a>

###### 3.1.4.8.1 Participant Disposition

<a id="topic-3.1.4.8.1-1"></a>

###### No discontinuations in the single-dose cohorts

> “There were no study drug discontinuations in the SAD cohorts in both studies as participants only received a single dose of study drug.”

Source: [Egbuna et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11006409/)

<a id="topic-3.1.4.8.1-2"></a>

###### Discontinuation for papular rash in the 45 mg once daily group of Study 1

> “Participant in the inaxaplin 45 mg once daily MAD group discontinued study drug due to AE of papular rash; AE was mild in severity and considered by the investigator as unlikely related to study drug.”

Source: [Egbuna et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11006409/)

<a id="topic-3.1.4.8.1-3"></a>

###### Disposition pooled across Study 1 and Study 2

| Disposition | Placebo | Inaxaplin total |
| --- | --- | --- |
| Completed study drug (SAD only), n/N (%) | “21/21 (100.0)” | “63/63 (100.0)” |
| Completed study drug (MAD only), n/N (%) | “18/23 (78.3)” | “50/71 (70.4)” |
| Discontinued study drug (MAD only), n/N (%) | “5/23 (21.7)” | “21/71 (29.6)” |
| Discontinued for adverse event | “0” | “3/71 (4.2)” |
| Participant refused further dosing (not due to AE) | “0” | “1/71 (1.4)” |
| Other non-adherence | “0” | “1/71 (1.4)” |
| Sponsor decision | “5/23 (21.7)” | “16/71 (22.5)” |

Source: [Egbuna et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11006409/)

<a id="heading-3.1.4.8.2"></a>

###### 3.1.4.8.2 Baseline Characteristics

<a id="topic-3.1.4.8.2-1"></a>

###### Demographics pooled across Study 1 and Study 2

| Characteristic | Placebo (N = 44) | Inaxaplin total (N = 134) |
| --- | --- | --- |
| Male, n (%) | “41 (93.2)” | “128 (95.5)” |
| Female, n (%) | “3 (6.8)” | “6 (4.5)” |
| Age (years), mean (±SD) | “36.7 (11.3)” | “36.6 (11.6)” |
| BMI (kg/m2), mean (±SD) | “27.07 (3.14)” | “26.22 (3.30)” |
| White, n (%) | “30 (68.2)” | “94 (70.1)” |
| Black or African American, n (%) | “12 (27.3)” | “32 (23.9)” |
| Asian, n (%) | “0” | “1 (0.7)” |
| American Indian or Alaska Native, n (%) | “0” | “3 (2.2)” |
| Multiracial, n (%) | “1 (2.3)” | “4 (3.0)” |
| Other race, n (%) | “1 (2.3)” | “0” |
| Hispanic or Latino, n (%) | “10 (22.7)” | “21 (15.7)” |
| Not Hispanic or Latino, n (%) | “34 (77.3)” | “113 (84.3)” |

Source: [Egbuna et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11006409/)

<a id="topic-3.1.4.8.2-2"></a>

###### Age and comparability of groups

> “The mean (± standard deviation) age of all participants was 36.7 (±11.5) years. Demographics and baseline characteristics were similar across the inaxaplin and placebo groups.”

Source: [Egbuna et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11006409/)

<a id="heading-3.1.4.8.3"></a>

###### 3.1.4.8.3 Efficacy Results

<a id="topic-3.1.4.8.3-1"></a>

###### Dose proportionality and half-life across both studies

> “The PK of inaxaplin was generally dose proportional, and the variability in PK parameters was generally low and did not appear to change across the dose range (online Table S1). Half-life was consistent across both studies ranging from approximately 13.3 to 22.9 h, which supports once daily dosing (online Table S1).”

Source: [Egbuna et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11006409/)

<a id="topic-3.1.4.8.3-2"></a>

###### Renal clearance as a minor excretion pathway

> “Renal clearance was a minor excretion pathway for inaxaplin; dose adjustments are therefore not anticipated for the intended patient population which will include patients with renal function impairment (online Table S2).”

Source: [Egbuna et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11006409/)

<a id="topic-3.1.4.8.3-3"></a>

###### No clinically significant interaction with midazolam

> “There were no clinically significant PK drug-drug interactions between inaxaplin and midazolam (online Table S3).”
> “Inaxaplin is not a clinically significant inhibitor or inducer of CYP3A4.”

Source: [Egbuna et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11006409/)

<a id="heading-3.1.4.8.4"></a>

###### 3.1.4.8.4 Health-related Quality of Life and Patient-reported Outcomes

Not applicable.

<a id="heading-3.1.4.8.5"></a>

###### 3.1.4.8.5 Safety Results

<a id="topic-3.1.4.8.5-1"></a>

###### Adverse events in the MAD cohorts of Study 1

| n (%) | Placebo (N = 9) | Inaxaplin 15 mg once daily (N = 9) | Inaxaplin 15 mg twice daily (N = 9) | Inaxaplin 45 mg once daily (N = 9) | Inaxaplin total (N = 27) |
| --- | --- | --- | --- | --- | --- |
| Participants with any AEs | “2 (22.2)” | “4 (44.4)” | “5 (55.6)” | “1 (11.1)” | “10 (37.0)” |
| Mild AEs | “2 (22.2)” | “4 (44.4)” | “5 (55.6)” | “1 (11.1)” | “10 (37.0)” |
| Moderate AEs | “0” | “0” | “0” | “0” | “0” |
| Participants with SAEs | “0” | “0” | “0” | “0” | “0” |
| AEs leading to treatment discontinuation | “0” | “0” | “0” | “1 (11.1)” | “1 (3.7)” |
| Headache | “0” | “1 (11.1)” | “2 (22.2)” | “0” | “3 (11.1)” |
| Fatigue | “1 (11.1)” | “2 (22.2)” | “0” | “0” | “2 (7.4)” |
| Cough | “0” | “3 (33.3)” | “0” | “0” | “3 (11.1)” |
| Dyspepsia | “0” | “0” | “3 (33.3)” | “0” | “3 (11.1)” |
| Constipation | “0” | “0” | “2 (22.2)” | “0” | “2 (7.4)” |
| Oropharyngeal pain | “0” | “1 (11.1)” | “1 (11.1)” | “0” | “2 (7.4)” |
| Throat irritation | “0” | “1 (11.1)” | “1 (11.1)” | “0” | “2 (7.4)” |
| Rhinorrhea | “1 (11.1)” | “1 (11.1)” | “0” | “0” | “1 (3.7)” |
| Sneezing | “1 (11.1)” | “1 (11.1)” | “0” | “0” | “1 (3.7)” |

Source: [Egbuna et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11006409/)

<a id="topic-3.1.4.8.5-2"></a>

###### Papular rash leading to discontinuation in Study 1

> “One participant in the inaxaplin 45 mg once daily MAD group in Study 1 discontinued treatment due to an AE of papular rash, which was mild in severity, resolved without treatment, and was considered unlikely related to the study drug by the investigator (Table 4).”

Source: [Egbuna et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11006409/)

<a id="topic-3.1.4.8.5-3"></a>

###### Adverse events pooled across Study 1 and Study 2

| n (%) | Placebo (N = 44) | Inaxaplin total (N = 134) |
| --- | --- | --- |
| Participants with any AEs | “10 (22.7)” | “33 (24.6)” |
| Mild AEs | “9 (20.5)” | “29 (21.6)” |
| Moderate AEs | “1 (2.3)” | “4 (3.0)” |
| Participants with SAEs | “0” | “0” |
| AEs leading to treatment discontinuation | “0” | “3 (2.2)” |
| Headache | “1 (2.3)” | “14 (10.4)” |
| Fatigue | “2 (4.5)” | “2 (1.5)” |
| Diarrhea | “0” | “4 (3.0)” |
| COVID-19 | “0” | “3 (2.2)” |
| Cough | “0” | “3 (2.2)” |
| Dyspepsia | “0” | “3 (2.2)” |

Source: [Egbuna et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11006409/)

<a id="topic-3.1.4.8.5-4"></a>

###### Severity, relatedness, and headache across both studies

> “All AEs were mild or moderate in severity. None of the AEs were considered by the investigator as related to inaxaplin. There were no serious adverse events (SAEs) (Table 3).”
> “Most of these AEs had similar or lower incidences in the inaxaplin group compared to placebo, except for headache (10.4% in the inaxaplin group compared to 2.3% in the placebo group) (Table 3).”
> “The incidence of headache was lower in participants treated with doses of inaxaplin ≤45 mg once daily (11.1%) than in those treated with doses of inaxaplin ≥60 mg once daily (18.5%).”

Source: [Egbuna et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11006409/)

<a id="topic-3.1.4.8.5-5"></a>

###### Laboratory values, vital signs, and ECG parameters

> “During the course of the SAD and MAD cohorts of both phase 1 studies, no clinically relevant trends were noted in any of the clinical laboratory results. Specifically, mean serum creatinine concentrations, serum lipid profile (i.e., total cholesterol, HDL cholesterol, LDL cholesterol, and triglyceride concentrations), and leukocyte counts were similar between the inaxaplin and placebo groups for all timepoints.”
> “There was no evidence of effects of inaxaplin on ECG parameters. There were no participants with a maximum QT interval corrected by Fridericia’s formula (QTcF; calculated from ECG assessments) interval >480 msec. No participants in the SAD or MAD cohorts had a QTcF interval increase >60 msec.”

Source: [Egbuna et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11006409/)

<a id="heading-3.1.4.9"></a>

##### 3.1.4.9 Study Limitations

<a id="topic-3.1.4.9-1"></a>

###### Summary: study limitations

VX18-147-001 enrolled healthy adults, so its safety findings do not describe people with APOL1-mediated kidney disease. Multiple dosing lasted 14 days, and each MAD group of Study 1 had 9 participants receiving inaxaplin (15 mg once daily, 15 mg twice daily, or 45 mg once daily) and 9 receiving pooled placebo. Across both phase 1 studies, 128 of 134 participants receiving inaxaplin (95.5%) were male, which the authors attribute to the exclusion of women of childbearing potential. The publication reports demographics, disposition, and the overall adverse event table pooled across Study 1 and Study 2, and gives the pharmacokinetic parameter estimates, including the midazolam interaction results, only in online supplementary tables. The trials were designed and funded by Vertex Pharmaceuticals, and four of the authors are Vertex employees who own stock or stock options in the company.

Source: [Egbuna et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11006409/)

<a id="topic-3.1.4.9-2"></a>

###### Predominantly male participants

> “A limitation of these studies, like most phase 1 studies, is that participants were predominantly men (owing to exclusion of women of childbearing age).”

Source: [Egbuna et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11006409/)

<a id="topic-3.1.4.9-3"></a>

###### Sponsor funding and employment

> “These studies were supported by Vertex Pharmaceuticals.”
> “Drs. Ogo Egbuna, George Manos, Simon Tian, and Fanuel Hagos are employees of Vertex Pharmaceuticals and own stock or stock options in the company.”

Source: [Egbuna et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11006409/)

<a id="heading-3.1.5"></a>

#### 3.1.5 VX20-147-008

<a id="heading-3.1.5.1"></a>

##### 3.1.5.1 Objective

<a id="topic-3.1.5.1-1"></a>

###### Aims of the two phase 1 studies

> “We conducted two phase 1 studies evaluating the safety, tolerability, and pharmacokinetics of single-ascending doses (SAD) and multiple-ascending doses (MAD) of inaxaplin in healthy participants.”

Source: [Egbuna et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11006409/)

<a id="topic-3.1.5.1-2"></a>

###### Higher-dose study VX20-147-008

> “To provide additional clinical information on the safety of higher doses of inaxaplin, a second phase 1 study of inaxaplin (Study VX20-147-008 or Study 2) evaluated single ascending doses of 90 mg up to 165 mg and multiple ascending doses of 60 mg up to 120 mg once daily in healthy participants.”

Source: [Egbuna et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11006409/)

<a id="topic-3.1.5.1-3"></a>

###### Primary objective: safety and tolerability

> “The primary objective for Parts A and B of both phase 1 studies was to determine safety and tolerability based on assessment of adverse events (AEs), clinical laboratory assessments (serum chemistry, hematology, coagulation, and urinalysis), standard 12-lead ECG measures (performed in triplicate), and vital signs.”

Source: [Egbuna et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11006409/)

<a id="heading-3.1.5.2"></a>

##### 3.1.5.2 Location and Study Date

<a id="topic-3.1.5.2-1"></a>

###### Site and dates of Study 2

> “Study 2 was conducted at one site in the United States (Salt Lake City, UT) between August 2020 and March 2021.”

Source: [Egbuna et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11006409/)

<a id="topic-3.1.5.2-2"></a>

###### Ethics approval

> “The study protocols were approved by the Advarra Institutional Review Board in the United States (Advarra IRB Identifiers: Pro00035356, Pro00034297, and Pro00044276).”

Source: [Egbuna et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11006409/)

<a id="heading-3.1.5.3"></a>

##### 3.1.5.3 Study Design

<a id="topic-3.1.5.3-1"></a>

###### Randomized, double-blind, placebo-controlled SAD/MAD design

> “We conducted two phase 1, randomized, double-blind, placebo-controlled SAD/MAD studies of inaxaplin in healthy participants.”

Source: [Egbuna et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11006409/)

<a id="topic-3.1.5.3-2"></a>

###### Part A single ascending doses and Part B multiple ascending doses

> “Part A of both phase 1 studies was designed to evaluate the safety and tolerability of single oral ascending doses of inaxaplin administered to healthy participants.”
> “Part B of both phase 1 studies was designed to evaluate the safety and tolerability of multiple oral ascending doses of inaxaplin administered to healthy participants.”

Source: [Egbuna et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11006409/)

<a id="topic-3.1.5.3-3"></a>

###### Unique participants per cohort and safety follow-up

> “All SAD and MAD cohorts included unique participants. There was no cross-over of participants within or across study cohorts. All participants had a Safety Follow-up Visit 7–10 days after the last dose of study drug.”

Source: [Egbuna et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11006409/)

<a id="topic-3.1.5.3-4"></a>

###### Repetition of two MAD cohorts

> “The inaxaplin 60 mg once daily and 90 mg once daily MAD cohorts in Study 2 were repeated with a distinct set of participants.”

Source: [Egbuna et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11006409/)

<a id="topic-3.1.5.3-5"></a>

###### Sponsor design of the trials

> “These trials were designed by Vertex Pharmaceuticals.”

Source: [Egbuna et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11006409/)

<a id="heading-3.1.5.4"></a>

##### 3.1.5.4 Eligibility Criteria

<a id="topic-3.1.5.4-1"></a>

###### Healthy adults of non-childbearing potential

> “In both studies, we enrolled healthy men and women of non-childbearing potential who were at least 18 years of age with body weight of >50 kg and body mass index (BMI) 18.0 to 32.0 kg/m2.”
> “was defined by no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurement, standard 12-lead electrocardiogram (ECG), and clinical laboratory tests.”

Source: [Egbuna et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11006409/)

<a id="heading-3.1.5.5"></a>

##### 3.1.5.5 Treatment

<a id="topic-3.1.5.5-1"></a>

###### Single doses of 90 to 165 mg or placebo in Part A of Study 2

> “In Study 2, participants were randomized 3:1 to receive a single dose of inaxaplin (90 mg, 135 mg, 165 mg) or placebo.”

Source: [Egbuna et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11006409/)

<a id="topic-3.1.5.5-2"></a>

###### Multiple doses for 14 days or placebo in Part B of Study 2

> “In Study 2, participants were randomized 3:1 to receive multiple doses of inaxaplin (60 mg once daily, 90 mg once daily, 120 mg once daily) or placebo for 14 days.”

Source: [Egbuna et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11006409/)

<a id="heading-3.1.5.6"></a>

##### 3.1.5.6 Study Outcomes

<a id="heading-3.1.5.6.1"></a>

###### 3.1.5.6.1 Rationale for Using Safety and Tolerability Assessments as the Primary Endpoints

<a id="topic-3.1.5.6.1-1"></a>

###### Primary safety and tolerability endpoints at higher doses

> “To provide additional clinical information on the safety of higher doses of inaxaplin, a second phase 1 study of inaxaplin (Study VX20-147-008 or Study 2) evaluated single ascending doses of 90 mg up to 165 mg and multiple ascending doses of 60 mg up to 120 mg once daily in healthy participants.”
> “The primary objective for Parts A and B of both phase 1 studies was to determine safety and tolerability based on assessment of adverse events (AEs), clinical laboratory assessments (serum chemistry, hematology, coagulation, and urinalysis), standard 12-lead ECG measures (performed in triplicate), and vital signs.”

Source: [Egbuna et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11006409/)

<a id="topic-3.1.5.6.1-2"></a>

###### Pharmacokinetic assessments

> “In both studies, we assessed plasma pharmacokinetic (PK) parameter estimates of inaxaplin (i.e., time of maximum concentration [tmax], maximum observed concentration [Cmax], area under the concentration vs. time curve from the time of dosing to 24 h [AUC0–24h], terminal phase half-life [t½], apparent volume of distribution [V/F], and apparent clearance at steady-state [CLss/F]) after multiple oral ascending doses of inaxaplin derived from plasma concentration-time data. We also assessed urine PK parameter estimates.”

Source: [Egbuna et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11006409/)

<a id="heading-3.1.5.7"></a>

##### 3.1.5.7 Statistical Analysis Description

<a id="heading-3.1.5.7.1"></a>

###### 3.1.5.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.5.7.1-1"></a>

###### Participants randomized and dosed across both studies

> “One hundred and seventy eight participants were randomized and received at least one dose of study drug in the SAD and MAD cohorts of the two phase 1 studies.”
> “There were 21 participants who received placebo in the SAD cohort and 23 participants who received placebo in the MAD cohort.”
> “There were 63 participants who received inaxaplin in the SAD cohort and 71 participants who received inaxaplin in the MAD cohort.”

Source: [Egbuna et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11006409/)

<a id="topic-3.1.5.7.1-2"></a>

###### Participants per group in the completed MAD cohorts of Study 2

> “Inaxaplin 60 mg once daily (N = 9)”
> “Inaxaplin 90 mg once daily (N = 9)”
> “Inaxaplin 120 mg once daily (N = 9)”
> “Placebo is pooled from MAD cohorts in Study 2 (except for the two MAD cohorts that were prematurely discontinued based on sponsor decision).”

Source: [Egbuna et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11006409/)

<a id="heading-3.1.5.7.2"></a>

###### 3.1.5.7.2 Description of Analysis Sets

<a id="topic-3.1.5.7.2-1"></a>

###### Safety set excluding the prematurely discontinued MAD cohorts

> “N, Safety Set sample size”
> “This table includes all participants in the MAD cohorts of Study 2 who were not prematurely discontinued and who received at least one dose of study drug.”
> “A summary of AEs for the SAD and MAD cohorts of both phase 1 studies is presented in Table 3; this table includes the two MAD cohorts in Study 2 that were prematurely discontinued by the sponsor due to ECG equipment malfunction and COVID-19 infection.”

Source: [Egbuna et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11006409/)

<a id="topic-3.1.5.7.2-2"></a>

###### Descriptive analyses, triplicate ECGs, and pooled analysis across cohorts

> “In both phase 1 studies, we used descriptive analyses on safety data including AEs, clinical laboratory assessments, vital signs, and ECGs.”
> “Since ECGs were performed in triplicate, the mean of each individual ECG parameter measurement (i.e., PR, RR, QRS, QT, QTcF, heart rate) at each specific visit and time point was used as the ECG for that specific visit and time point for summary purposes. In addition to analyses performed in the SAD and MAD cohorts separately for the two studies, we conducted a pooled analysis across cohorts.”

Source: [Egbuna et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11006409/)

<a id="heading-3.1.5.8"></a>

##### 3.1.5.8 Results

<a id="heading-3.1.5.8.1"></a>

###### 3.1.5.8.1 Participant Disposition

<a id="topic-3.1.5.8.1-1"></a>

###### No discontinuations in the single-dose cohorts

> “There were no study drug discontinuations in the SAD cohorts in both studies as participants only received a single dose of study drug.”

Source: [Egbuna et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11006409/)

<a id="topic-3.1.5.8.1-2"></a>

###### Two MAD cohorts discontinued by sponsor decision

> “In the Study 2, 21 participants in two MAD cohorts discontinued treatment due to sponsor decision; this includes 12 participants (inaxaplin 60 mg once daily group: N = 9; placebo group: N = 3) who discontinued study drug due to ECG equipment malfunction and 9 participants (inaxaplin 90 mg once daily group: N = 7; placebo group: N = 2) who discontinued study drug due to the impact of the COVID-19 pandemic.”
> “Dosing in one cohort (inaxaplin 60 mg once daily MAD group: N = 9; placebo MAD group: N = 3) was paused to investigate an ECG finding in a single participant that was ultimately found to be due to ECG equipment malfunction (dosing was stopped prior to day 2 dose for the incident participant and prior to day 3 dose in all other participants). As dosing was interrupted, the cohort was discontinued per sponsor decision.”
> “Due to possible exposure to infection, the sponsor decided to discontinue the remainder of the cohort (inaxaplin 90 mg once daily MAD group: N = 7; placebo MAD group: N = 2) on day 2.”

Source: [Egbuna et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11006409/)

<a id="topic-3.1.5.8.1-3"></a>

###### Discontinuations for adverse events in Study 2

> “Participant in the inaxaplin 60 mg once daily treatment group discontinued study drug due to an AE of tachycardia; AE was mild in severity and considered by the investigator as not related to study drug.”
> “In Study 2, one participant in the inaxaplin 90 mg once daily MAD group discontinued treatment due to the AE of COVID-19 (as described above), which was moderate in severity, resolved without treatment, and was considered by the investigator as not related to inaxaplin (Table 3).”

Source: [Egbuna et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11006409/)

<a id="topic-3.1.5.8.1-4"></a>

###### Disposition pooled across Study 1 and Study 2

| Disposition | Placebo | Inaxaplin total |
| --- | --- | --- |
| Completed study drug (SAD only), n/N (%) | “21/21 (100.0)” | “63/63 (100.0)” |
| Completed study drug (MAD only), n/N (%) | “18/23 (78.3)” | “50/71 (70.4)” |
| Discontinued study drug (MAD only), n/N (%) | “5/23 (21.7)” | “21/71 (29.6)” |
| Discontinued for adverse event | “0” | “3/71 (4.2)” |
| Participant refused further dosing (not due to AE) | “0” | “1/71 (1.4)” |
| Other non-adherence | “0” | “1/71 (1.4)” |
| Sponsor decision | “5/23 (21.7)” | “16/71 (22.5)” |

Source: [Egbuna et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11006409/)

<a id="heading-3.1.5.8.2"></a>

###### 3.1.5.8.2 Baseline Characteristics

<a id="topic-3.1.5.8.2-1"></a>

###### Demographics pooled across Study 1 and Study 2

| Characteristic | Placebo (N = 44) | Inaxaplin total (N = 134) |
| --- | --- | --- |
| Male, n (%) | “41 (93.2)” | “128 (95.5)” |
| Female, n (%) | “3 (6.8)” | “6 (4.5)” |
| Age (years), mean (±SD) | “36.7 (11.3)” | “36.6 (11.6)” |
| BMI (kg/m2), mean (±SD) | “27.07 (3.14)” | “26.22 (3.30)” |
| White, n (%) | “30 (68.2)” | “94 (70.1)” |
| Black or African American, n (%) | “12 (27.3)” | “32 (23.9)” |
| Asian, n (%) | “0” | “1 (0.7)” |
| American Indian or Alaska Native, n (%) | “0” | “3 (2.2)” |
| Multiracial, n (%) | “1 (2.3)” | “4 (3.0)” |
| Other race, n (%) | “1 (2.3)” | “0” |
| Hispanic or Latino, n (%) | “10 (22.7)” | “21 (15.7)” |
| Not Hispanic or Latino, n (%) | “34 (77.3)” | “113 (84.3)” |

Source: [Egbuna et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11006409/)

<a id="topic-3.1.5.8.2-2"></a>

###### Age and comparability of groups

> “The mean (± standard deviation) age of all participants was 36.7 (±11.5) years. Demographics and baseline characteristics were similar across the inaxaplin and placebo groups.”

Source: [Egbuna et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11006409/)

<a id="heading-3.1.5.8.3"></a>

###### 3.1.5.8.3 Efficacy Results

<a id="topic-3.1.5.8.3-1"></a>

###### Dose proportionality and half-life up to 120 mg once daily

> “The PK of inaxaplin was generally dose proportional, and the variability in PK parameters was generally low and did not appear to change across the dose range (online Table S1). Half-life was consistent across both studies ranging from approximately 13.3 to 22.9 h, which supports once daily dosing (online Table S1).”
> “It exhibits dose proportional PK with low variability across doses up to 120 mg once daily for 14 days with a half-life ranging from 13.3 to 22.9 h.”

Source: [Egbuna et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11006409/)

<a id="topic-3.1.5.8.3-2"></a>

###### Renal clearance as a minor excretion pathway

> “Renal clearance was a minor excretion pathway for inaxaplin; dose adjustments are therefore not anticipated for the intended patient population which will include patients with renal function impairment (online Table S2).”

Source: [Egbuna et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11006409/)

<a id="heading-3.1.5.8.4"></a>

###### 3.1.5.8.4 Health-related Quality of Life and Patient-reported Outcomes

Not applicable.

<a id="heading-3.1.5.8.5"></a>

###### 3.1.5.8.5 Safety Results

<a id="topic-3.1.5.8.5-1"></a>

###### Adverse events in the completed MAD cohorts of Study 2

| n (%) | Placebo (N = 9) | Inaxaplin 60 mg once daily (N = 9) | Inaxaplin 90 mg once daily (N = 9) | Inaxaplin 120 mg once daily (N = 9) | Inaxaplin total (N = 27) |
| --- | --- | --- | --- | --- | --- |
| Participants with any AEs | “5 (55.6)” | “6 (66.7)” | “3 (33.3)” | “3 (33.3)” | “12 (44.4)” |
| Mild AEs | “4 (44.4)” | “6 (66.7)” | “3 (33.3)” | “3 (33.3)” | “12 (44.4)” |
| Moderate AEs | “1 (11.1)” | “0” | “0” | “0” | “0” |
| Participants with SAEs | “0” | “0” | “0” | “0” | “0” |
| AEs leading to treatment discontinuation | “0” | “1 (11.1)” | “0” | “0” | “1 (3.7)” |
| Headache | “0” | “2 (22.2)” | “1 (11.1)” | “2 (22.2)” | “5 (18.5)” |
| Palpitations | “1 (11.1)” | “0” | “1 (11.1)” | “0” | “1 (3.7)” |
| Abdominal pain | “1 (11.1)” | “0” | “0” | “1 (11.1)” | “1 (3.7)” |
| Diarrhea | “0” | “0” | “1 (11.1)” | “1 (11.1)” | “2 (7.4)” |

Source: [Egbuna et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11006409/)

<a id="topic-3.1.5.8.5-2"></a>

###### Adverse events in the two prematurely discontinued MAD cohorts

> “In the two MAD cohorts from Study 2 that were prematurely discontinued due to sponsor decision, there were eight AEs including four AEs of headache (one in the placebo group; three in the inaxaplin group), two AEs of COVID-19 (both in the inaxaplin group), one AE of fatigue (placebo group) and one AE of dyspnea (inaxaplin group).”

Source: [Egbuna et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11006409/)

<a id="topic-3.1.5.8.5-3"></a>

###### Tachycardia leading to discontinuation in Study 2

> “One participant in the inaxaplin 60 mg once daily MAD group in Study 2 discontinued treatment due to an AE of tachycardia (Table 5); this participant reported anxiety as an AE (of mild intensity) and reported similar instances of test anxiety in the past. The AE of tachycardia was considered mild in severity, resolved without treatment, and was considered by the investigator as not related to study drug.”

Source: [Egbuna et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11006409/)

<a id="topic-3.1.5.8.5-4"></a>

###### Adverse events pooled across Study 1 and Study 2

| n (%) | Placebo (N = 44) | Inaxaplin total (N = 134) |
| --- | --- | --- |
| Participants with any AEs | “10 (22.7)” | “33 (24.6)” |
| Mild AEs | “9 (20.5)” | “29 (21.6)” |
| Moderate AEs | “1 (2.3)” | “4 (3.0)” |
| Participants with SAEs | “0” | “0” |
| AEs leading to treatment discontinuation | “0” | “3 (2.2)” |
| Headache | “1 (2.3)” | “14 (10.4)” |
| Fatigue | “2 (4.5)” | “2 (1.5)” |
| Diarrhea | “0” | “4 (3.0)” |
| COVID-19 | “0” | “3 (2.2)” |
| Cough | “0” | “3 (2.2)” |
| Dyspepsia | “0” | “3 (2.2)” |

Source: [Egbuna et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11006409/)

<a id="topic-3.1.5.8.5-5"></a>

###### Severity, relatedness, and headache across both studies

> “All AEs were mild or moderate in severity. None of the AEs were considered by the investigator as related to inaxaplin. There were no serious adverse events (SAEs) (Table 3).”
> “Inaxaplin was generally well tolerated at single doses up to 165 mg and at multiple doses up to 120 mg once daily for 14 days.”
> “The incidence of headache was lower in participants treated with doses of inaxaplin ≤45 mg once daily (11.1%) than in those treated with doses of inaxaplin ≥60 mg once daily (18.5%).”

Source: [Egbuna et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11006409/)

<a id="topic-3.1.5.8.5-6"></a>

###### Laboratory values, vital signs, and ECG parameters

> “During the course of the SAD and MAD cohorts of both phase 1 studies, no clinically relevant trends were noted in any of the clinical laboratory results. Specifically, mean serum creatinine concentrations, serum lipid profile (i.e., total cholesterol, HDL cholesterol, LDL cholesterol, and triglyceride concentrations), and leukocyte counts were similar between the inaxaplin and placebo groups for all timepoints.”
> “There was no evidence of effects of inaxaplin on ECG parameters. There were no participants with a maximum QT interval corrected by Fridericia’s formula (QTcF; calculated from ECG assessments) interval >480 msec. No participants in the SAD or MAD cohorts had a QTcF interval increase >60 msec.”

Source: [Egbuna et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11006409/)

<a id="heading-3.1.5.9"></a>

##### 3.1.5.9 Study Limitations

<a id="topic-3.1.5.9-1"></a>

###### Summary: study limitations

VX20-147-008 enrolled healthy adults at one United States site and tested single doses of 90 to 165 mg and multiple doses of 60 to 120 mg once daily, above the 15 mg and 45 mg once daily doses being evaluated in the phase 2/3 trial, with multiple dosing limited to 14 days. Two of its MAD cohorts were stopped early by sponsor decision: 12 participants after an ECG finding attributed to equipment malfunction and 9 participants because of possible COVID-19 exposure, and both cohorts were repeated with new participants. The Study 2 MAD adverse event table therefore excludes these cohorts and has 9 participants in each dose group and 9 receiving pooled placebo, while the pooled adverse event table includes them. Across both phase 1 studies, 128 of 134 participants receiving inaxaplin (95.5%) were male, which the authors attribute to the exclusion of women of childbearing potential. Pharmacokinetic parameter estimates appear only in online supplementary tables, and the trials were designed and funded by Vertex Pharmaceuticals.

Source: [Egbuna et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11006409/)

<a id="topic-3.1.5.9-2"></a>

###### Predominantly male participants

> “A limitation of these studies, like most phase 1 studies, is that participants were predominantly men (owing to exclusion of women of childbearing age).”

Source: [Egbuna et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11006409/)

<a id="topic-3.1.5.9-3"></a>

###### Interrupted and repeated MAD cohorts

> “The majority of treatment discontinuations occurred in two MAD cohorts of Study 2 and were due to sponsor decision (21 participants).”
> “The inaxaplin 60 mg once daily and 90 mg once daily MAD cohorts in Study 2 were repeated with a distinct set of participants.”

Source: [Egbuna et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11006409/)

<a id="topic-3.1.5.9-4"></a>

###### Sponsor funding and employment

> “These studies were supported by Vertex Pharmaceuticals.”
> “Drs. Ogo Egbuna, George Manos, Simon Tian, and Fanuel Hagos are employees of Vertex Pharmaceuticals and own stock or stock options in the company.”

Source: [Egbuna et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11006409/)

<a id="heading-3.1.6"></a>

#### 3.1.6 VX19-147-007

<a id="heading-3.1.6.1"></a>

##### 3.1.6.1 Objective

<a id="topic-3.1.6.1-1"></a>

###### Purpose stated in the registry record

> “The purpose of this study is to evaluate the pharmacokinetics and safety of a single dose of Inaxaplin (IXP) in participants with severe renal impairment and healthy participants with normal renal function.”

Source: [ClinicalTrials.gov NCT05865171](https://clinicaltrials.gov/study/NCT05865171)

<a id="topic-3.1.6.1-2"></a>

###### Aim stated in the congress abstract

> “We evaluated the pharmacokinetics (PK) of IXP in participants with renal or hepatic impairment compared to the PK in matched healthy participants in 2 separate studies.”

Source: [Hosey et al. (2026)](https://www.ajkd.org/article/S0272-6386%2826%2900494-4/pdf)

<a id="heading-3.1.6.2"></a>

##### 3.1.6.2 Location and Study Date

<a id="topic-3.1.6.2-1"></a>

###### Study dates and status in the registry record

| Field | Registry entry |
| --- | --- |
| Recruitment status | “Completed” |
| Study start (actual) | “2023-06-12” |
| Primary completion (actual) | “2024-06-12” |
| Study completion (actual) | “2024-06-12” |
| First posted | “2023-05-18” |
| Last update posted | “2024-07-12” |
| Other study ID numbers | “VX19-147-007” |

Source: [ClinicalTrials.gov NCT05865171](https://clinicaltrials.gov/study/NCT05865171)

<a id="topic-3.1.6.2-2"></a>

###### Study locations in the registry record

> “This study has 2 locations”
> “Ocala, Florida, United States, 34471”
> “Tampa, Florida, United States, 33603”

Source: [ClinicalTrials.gov NCT05865171](https://clinicaltrials.gov/study/NCT05865171)

<a id="topic-3.1.6.2-3"></a>

###### Presentation at the NKF 2026 Spring Clinical Meetings

> “NKF 2026 Spring Clinical Meetings Abstracts”

Source: [Hosey et al. (2026)](https://www.ajkd.org/article/S0272-6386%2826%2900494-4/pdf)

<a id="heading-3.1.6.3"></a>

##### 3.1.6.3 Study Design

<a id="topic-3.1.6.3-1"></a>

###### Phase 1, open-label, single-dose design

> “A Phase 1, Open-label Study Evaluating the Pharmacokinetics and Safety of a Single Dose of Inaxaplin in Subjects With Severe Renal Impairment and Healthy Subjects With Normal Renal Function”

Source: [ClinicalTrials.gov NCT05865171](https://clinicaltrials.gov/study/NCT05865171)

<a id="topic-3.1.6.3-2"></a>

###### Design details in the registry record

| Field | Registry entry |
| --- | --- |
| Study type | “Interventional” |
| Phase | “Phase 1” |
| Primary purpose | “Basic Science” |
| Allocation | “Randomized” |
| Interventional model | “Sequential Assignment” |
| Masking | “None (Open Label)” |

Source: [ClinicalTrials.gov NCT05865171](https://clinicaltrials.gov/study/NCT05865171)

<a id="topic-3.1.6.3-3"></a>

###### Comparison with matched healthy participants

> “We compared systemic exposures of IXP to matched healthy participants using geometric least squares mean ratios (GLSMR).”

Source: [Hosey et al. (2026)](https://www.ajkd.org/article/S0272-6386%2826%2900494-4/pdf)

<a id="heading-3.1.6.4"></a>

##### 3.1.6.4 Eligibility Criteria

<a id="topic-3.1.6.4-1"></a>

###### Severe renal impairment not on dialysis

> “severe renal impairment (estimated glomerular filtration rate of <30 mL/min and not on dialysis)”

Source: [Hosey et al. (2026)](https://www.ajkd.org/article/S0272-6386%2826%2900494-4/pdf)

<a id="topic-3.1.6.4-2"></a>

###### Key criteria in the registry record

> “Body mass index (BMI) of 18.5 to 40.0 kilogram per meter square (kg/m^2)”
> “Stable renal function for at least 1 month prior to enrollment”
> “Uncontrolled hypertension”
> “Any condition possibly affecting drug absorption”
> “Other protocol defined Inclusion/Exclusion criteria may apply.”

Source: [ClinicalTrials.gov NCT05865171](https://clinicaltrials.gov/study/NCT05865171)

<a id="topic-3.1.6.4-3"></a>

###### Age range and healthy volunteers

| Field | Registry entry |
| --- | --- |
| Ages eligible | “18 Years to 80 Years” |
| Sexes eligible | “All” |
| Accepts healthy volunteers | “Yes” |

Source: [ClinicalTrials.gov NCT05865171](https://clinicaltrials.gov/study/NCT05865171)

<a id="heading-3.1.6.5"></a>

##### 3.1.6.5 Treatment

<a id="topic-3.1.6.5-1"></a>

###### Single 45 mg oral dose

> “evaluated the PK and safety of IXP following a single 45-mg oral dose”

Source: [Hosey et al. (2026)](https://www.ajkd.org/article/S0272-6386%2826%2900494-4/pdf)

<a id="topic-3.1.6.5-2"></a>

###### Arms in the registry record

> “Experimental: Cohort 1: Severe Renal Impairment”
> “Experimental: Cohort 1: Healthy Participants”
> “Participants will receive a single dose of IXP on Day 1.”
> “Tablets for oral administration.”

Source: [ClinicalTrials.gov NCT05865171](https://clinicaltrials.gov/study/NCT05865171)

<a id="heading-3.1.6.6"></a>

##### 3.1.6.6 Study Outcomes

<a id="heading-3.1.6.6.1"></a>

###### 3.1.6.6.1 Rationale for Using Plasma Cmax and AUC0-inf as the Primary Endpoints

<a id="topic-3.1.6.6.1-1"></a>

###### Registered primary and secondary outcomes

| Outcome | Measure | Time frame |
| --- | --- | --- |
| Primary | “Maximum Observed Plasma Concentration (Cmax) of IXP” | “Day 1 up to Day 7” |
| Primary | “Area Under the Concentration Versus Time Curve From the Time of Dosing Extrapolated to Infinity (AUC0-inf) of IXP” | “Day 1 up to Day 7” |
| Secondary | “Safety and Tolerability as Assessed by Number of Participants With Adverse events (AEs) and Serious Adverse Events (SAEs)” | “Day 1 through completion of study participation (up to a maximum of 17 days)” |

Source: [ClinicalTrials.gov NCT05865171](https://clinicaltrials.gov/study/NCT05865171)

<a id="topic-3.1.6.6.1-2"></a>

###### Elimination pathways of inaxaplin

> “IXP primarily undergoes hepatic metabolism, while renal clearance represents a minor pathway.”

Source: [Hosey et al. (2026)](https://www.ajkd.org/article/S0272-6386%2826%2900494-4/pdf)

<a id="topic-3.1.6.6.1-3"></a>

###### Renal clearance in the healthy-adult studies

> “Renal clearance was a minor excretion pathway for inaxaplin; dose adjustments are therefore not anticipated for the intended patient population which will include patients with renal function impairment (online Table S2).”

Source: [Egbuna et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11006409/)

<a id="heading-3.1.6.7"></a>

##### 3.1.6.7 Statistical Analysis Description

<a id="heading-3.1.6.7.1"></a>

###### 3.1.6.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.6.7.1-1"></a>

###### Enrollment in the registry record

| Field | Registry entry |
| --- | --- |
| Enrollment (actual) | “16” |

Source: [ClinicalTrials.gov NCT05865171](https://clinicaltrials.gov/study/NCT05865171)

<a id="topic-3.1.6.7.1-2"></a>

###### Enrollment reported in the congress abstract

> “Sixteen participants were enrolled in the renal study”

Source: [Hosey et al. (2026)](https://www.ajkd.org/article/S0272-6386%2826%2900494-4/pdf)

<a id="heading-3.1.6.7.2"></a>

###### 3.1.6.7.2 Description of Analysis Sets

No evidence found.

<a id="heading-3.1.6.8"></a>

##### 3.1.6.8 Results

<a id="heading-3.1.6.8.1"></a>

###### 3.1.6.8.1 Participant Disposition

No evidence found.

<a id="heading-3.1.6.8.2"></a>

###### 3.1.6.8.2 Baseline Characteristics

No evidence found.

<a id="heading-3.1.6.8.3"></a>

###### 3.1.6.8.3 Efficacy Results

<a id="topic-3.1.6.8.3-1"></a>

###### Exposure in severe renal impairment compared with healthy matches

> “There were no clinically meaningful differences observed in IXP exposures in participants with severe renal impairment (N=8) compared to their healthy matches (N=8; GLSMR <120%).”
> “No clinically meaningful differences in IXP PK were observed in patients with renal impairment or with mild to moderate hepatic impairment up to and including a CP score of 7. Therefore, no dose adjustment of IXP is anticipated in these populations.”

Source: [Hosey et al. (2026)](https://www.ajkd.org/article/S0272-6386%2826%2900494-4/pdf)

<a id="heading-3.1.6.8.4"></a>

###### 3.1.6.8.4 Health-related Quality of Life and Patient-reported Outcomes

Not applicable.

<a id="heading-3.1.6.8.5"></a>

###### 3.1.6.8.5 Safety Results

<a id="topic-3.1.6.8.5-1"></a>

###### Safety in the renal and hepatic impairment studies

> “IXP was generally safe and well tolerated in both studies.”

Source: [Hosey et al. (2026)](https://www.ajkd.org/article/S0272-6386%2826%2900494-4/pdf)

<a id="heading-3.1.6.9"></a>

##### 3.1.6.9 Study Limitations

<a id="topic-3.1.6.9-1"></a>

###### Summary: study limitations

VX19-147-007 gave a single 45 mg dose to 16 participants: 8 with severe renal impairment (estimated glomerular filtration rate below 30 mL/min and not on dialysis) and 8 matched healthy participants. The results are available only as a congress abstract, which reports the geometric least squares mean ratio as “<120%” without point estimates or confidence intervals and reports safety only as “generally safe and well tolerated”. The ClinicalTrials.gov record lists no posted results. Participants on dialysis and multiple-dose exposure were not studied, and five of the six abstract authors list a Vertex Pharmaceuticals affiliation.

Source: [ClinicalTrials.gov NCT05865171](https://clinicaltrials.gov/study/NCT05865171); [Hosey et al. (2026)](https://www.ajkd.org/article/S0272-6386%2826%2900494-4/pdf)

<a id="topic-3.1.6.9-2"></a>

###### Author affiliations of the congress abstract

> “Chelsea Hosey1, Vasco Oliveira1, Danieli Salinas1, Liz Minevich1, Glenn Chertow2, Swarupa Kulkarni1.”
> “1Vertex Pharmaceuticals Inc; 2Stanford University School of Medicine”

Source: [Hosey et al. (2026)](https://www.ajkd.org/article/S0272-6386%2826%2900494-4/pdf)

<a id="topic-3.1.6.9-3"></a>

###### No results posted in the registry record

> “No Results Posted”

Source: [ClinicalTrials.gov NCT05865171](https://clinicaltrials.gov/study/NCT05865171)

<a id="heading-3.1.7"></a>

#### 3.1.7 VX20-147-006

<a id="heading-3.1.7.1"></a>

##### 3.1.7.1 Objective

<a id="topic-3.1.7.1-1"></a>

###### Purpose stated in the registry record

> “The purpose of this study is to evaluate the pharmacokinetics, safety and tolerability of Inaxaplin (IXP) in participants with mild or moderate hepatic impairment and in matched healthy participants.”

Source: [ClinicalTrials.gov NCT06529796](https://clinicaltrials.gov/study/NCT06529796)

<a id="topic-3.1.7.1-2"></a>

###### Aim stated in the congress abstract

> “We evaluated the pharmacokinetics (PK) of IXP in participants with renal or hepatic impairment compared to the PK in matched healthy participants in 2 separate studies.”

Source: [Hosey et al. (2026)](https://www.ajkd.org/article/S0272-6386%2826%2900494-4/pdf)

<a id="heading-3.1.7.2"></a>

##### 3.1.7.2 Location and Study Date

<a id="topic-3.1.7.2-1"></a>

###### Study dates and status in the registry record

| Field | Registry entry |
| --- | --- |
| Recruitment status | “Completed” |
| Study start (actual) | “2024-08-02” |
| Primary completion (actual) | “2024-12-20” |
| Study completion (actual) | “2024-12-20” |
| First posted | “2024-07-31” |
| Last update posted | “2025-01-20” |
| Other study ID numbers | “VX20-147-006” |

Source: [ClinicalTrials.gov NCT06529796](https://clinicaltrials.gov/study/NCT06529796)

<a id="topic-3.1.7.2-2"></a>

###### Study locations in the registry record

> “This study has 3 locations”
> “Miami, Florida, United States, 33136”
> “St. Petersburg, Florida, United States, 33705”
> “San Antonio, Texas, United States, 78215”

Source: [ClinicalTrials.gov NCT06529796](https://clinicaltrials.gov/study/NCT06529796)

<a id="topic-3.1.7.2-3"></a>

###### Presentation at the NKF 2026 Spring Clinical Meetings

> “NKF 2026 Spring Clinical Meetings Abstracts”

Source: [Hosey et al. (2026)](https://www.ajkd.org/article/S0272-6386%2826%2900494-4/pdf)

<a id="heading-3.1.7.3"></a>

##### 3.1.7.3 Study Design

<a id="topic-3.1.7.3-1"></a>

###### Phase 1, open-label, single-dose design with matched healthy participants

> “A Phase 1, Open-label Study to Assess the Pharmacokinetics and Safety of a Single Dose of Inaxaplin in Subjects With Mild or Moderate Hepatic Impairment and in Matched Healthy Subjects”

Source: [ClinicalTrials.gov NCT06529796](https://clinicaltrials.gov/study/NCT06529796)

<a id="topic-3.1.7.3-2"></a>

###### Design details in the registry record

| Field | Registry entry |
| --- | --- |
| Study type | “Interventional” |
| Phase | “Phase 1” |
| Primary purpose | “Basic Science” |
| Allocation | “Non-Randomized” |
| Interventional model | “Parallel Assignment” |
| Masking | “None (Open Label)” |

Source: [ClinicalTrials.gov NCT06529796](https://clinicaltrials.gov/study/NCT06529796)

<a id="topic-3.1.7.3-3"></a>

###### Comparison with matched healthy participants

> “We compared systemic exposures of IXP to matched healthy participants using geometric least squares mean ratios (GLSMR).”

Source: [Hosey et al. (2026)](https://www.ajkd.org/article/S0272-6386%2826%2900494-4/pdf)

<a id="heading-3.1.7.4"></a>

##### 3.1.7.4 Eligibility Criteria

<a id="topic-3.1.7.4-1"></a>

###### Child-Pugh classes and matching of healthy participants

> “Cohort 1 (mild impairment): defined as a Child-Pugh total score of 5 to 6 (Child-Pugh Class A)”
> “Cohort 3 (moderate impairment): defined as a Child-Pugh total score of 7 to 9 (Child-Pugh Class B)”
> “Participants will be matched during screening to participants with mild (Cohort 1) or moderate (Cohort 3) hepatic impairment according to each of the following parameters: age (± 10 years); sex; and BMI (± 15%)”

Source: [ClinicalTrials.gov NCT06529796](https://clinicaltrials.gov/study/NCT06529796)

<a id="topic-3.1.7.4-2"></a>

###### Key exclusion criteria in the registry record

> “Acute febrile illness within 14 days and/or acute illness within 5 days before first dose of study drug”
> “Participants who smoke”
> “Any condition possibly affecting drug absorption”

Source: [ClinicalTrials.gov NCT06529796](https://clinicaltrials.gov/study/NCT06529796)

<a id="topic-3.1.7.4-3"></a>

###### Age range and healthy volunteers

| Field | Registry entry |
| --- | --- |
| Ages eligible | “18 Years to 75 Years” |
| Sexes eligible | “All” |
| Accepts healthy volunteers | “Yes” |

Source: [ClinicalTrials.gov NCT06529796](https://clinicaltrials.gov/study/NCT06529796)

<a id="heading-3.1.7.5"></a>

##### 3.1.7.5 Treatment

<a id="topic-3.1.7.5-1"></a>

###### Single 45 mg oral dose

> “evaluated the PK and safety of IXP following a single 45-mg oral dose”

Source: [Hosey et al. (2026)](https://www.ajkd.org/article/S0272-6386%2826%2900494-4/pdf)

<a id="topic-3.1.7.5-2"></a>

###### Arms in the registry record

> “Experimental: Cohort 1: Mild Hepatic Impairment”
> “Experimental: Cohort 2: Matched Healthy Participants”
> “Experimental: Cohort 3: Moderate Hepatic Impairment”
> “Experimental: Cohort 4: Matched Healthy Participants”
> “Tablet for oral administration.”

Source: [ClinicalTrials.gov NCT06529796](https://clinicaltrials.gov/study/NCT06529796)

<a id="heading-3.1.7.6"></a>

##### 3.1.7.6 Study Outcomes

<a id="heading-3.1.7.6.1"></a>

###### 3.1.7.6.1 Rationale for Using Plasma Cmax and AUC0-inf as the Primary Endpoints

<a id="topic-3.1.7.6.1-1"></a>

###### Registered primary and secondary outcomes

| Outcome | Measure | Time frame |
| --- | --- | --- |
| Primary | “Maximum Observed Plasma Concentration (Cmax) of IXP” | “From Day 1 up to Day 10” |
| Primary | “Area Under the Concentration Versus Time Curve From the Time of Dosing Extrapolated to Infinity (AUC0-inf) of IXP” | “From Day 1 up to Day 10” |
| Secondary | “Safety and Tolerability as Assessed by Number of Participants With Adverse events (AEs) and Serious Adverse Events (SAEs)” | “From Day 1 up to Day 20” |

Source: [ClinicalTrials.gov NCT06529796](https://clinicaltrials.gov/study/NCT06529796)

<a id="topic-3.1.7.6.1-2"></a>

###### Hepatic metabolism as the primary elimination pathway

> “IXP primarily undergoes hepatic metabolism, while renal clearance represents a minor pathway.”

Source: [Hosey et al. (2026)](https://www.ajkd.org/article/S0272-6386%2826%2900494-4/pdf)

<a id="heading-3.1.7.7"></a>

##### 3.1.7.7 Statistical Analysis Description

<a id="heading-3.1.7.7.1"></a>

###### 3.1.7.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.7.7.1-1"></a>

###### Enrollment in the registry record

| Field | Registry entry |
| --- | --- |
| Enrollment (actual) | “36” |

Source: [ClinicalTrials.gov NCT06529796](https://clinicaltrials.gov/study/NCT06529796)

<a id="topic-3.1.7.7.1-2"></a>

###### Enrollment reported in the congress abstract

> “36 participants were enrolled in the hepatic study”

Source: [Hosey et al. (2026)](https://www.ajkd.org/article/S0272-6386%2826%2900494-4/pdf)

<a id="heading-3.1.7.7.2"></a>

###### 3.1.7.7.2 Description of Analysis Sets

No evidence found.

<a id="heading-3.1.7.8"></a>

##### 3.1.7.8 Results

<a id="heading-3.1.7.8.1"></a>

###### 3.1.7.8.1 Participant Disposition

No evidence found.

<a id="heading-3.1.7.8.2"></a>

###### 3.1.7.8.2 Baseline Characteristics

No evidence found.

<a id="heading-3.1.7.8.3"></a>

###### 3.1.7.8.3 Efficacy Results

<a id="topic-3.1.7.8.3-1"></a>

###### Exposure in mild or moderate hepatic impairment compared with healthy matches

> “There were no clinically meaningful differences observed in participants with mild (N=10) or moderate (N=10) hepatic impairment compared to their healthy matches (N=16; GLSMR <125%).”

Source: [Hosey et al. (2026)](https://www.ajkd.org/article/S0272-6386%2826%2900494-4/pdf)

<a id="topic-3.1.7.8.3-2"></a>

###### Higher exposure in one participant with a Child-Pugh score of 9

> “One participant with a CP score of 9 had approximately a 2.2-fold higher AUC compared to participants with a CP score of 7 or below, suggesting a potential effect on IXP systemic exposure in the hepatically impaired participant with a CP score of 9.”

Source: [Hosey et al. (2026)](https://www.ajkd.org/article/S0272-6386%2826%2900494-4/pdf)

<a id="topic-3.1.7.8.3-3"></a>

###### Conclusion on dose adjustment

> “No clinically meaningful differences in IXP PK were observed in patients with renal impairment or with mild to moderate hepatic impairment up to and including a CP score of 7. Therefore, no dose adjustment of IXP is anticipated in these populations.”

Source: [Hosey et al. (2026)](https://www.ajkd.org/article/S0272-6386%2826%2900494-4/pdf)

<a id="heading-3.1.7.8.4"></a>

###### 3.1.7.8.4 Health-related Quality of Life and Patient-reported Outcomes

Not applicable.

<a id="heading-3.1.7.8.5"></a>

###### 3.1.7.8.5 Safety Results

<a id="topic-3.1.7.8.5-1"></a>

###### Safety in the renal and hepatic impairment studies

> “IXP was generally safe and well tolerated in both studies.”

Source: [Hosey et al. (2026)](https://www.ajkd.org/article/S0272-6386%2826%2900494-4/pdf)

<a id="heading-3.1.7.9"></a>

##### 3.1.7.9 Study Limitations

<a id="topic-3.1.7.9-1"></a>

###### Summary: study limitations

VX20-147-006 gave a single 45 mg dose to 36 participants: 10 with mild (Child-Pugh 5 to 6) and 10 with moderate (Child-Pugh 7 to 9) hepatic impairment, and 16 matched healthy participants. The abstract's conclusion of no clinically meaningful difference extends only “up to and including a CP score of 7”; one participant with a Child-Pugh score of 9 had an AUC about 2.2-fold higher than participants with scores of 7 or below. Severe hepatic impairment (Child-Pugh Class C) was outside the eligibility criteria. The results are available only as a congress abstract, which reports the geometric least squares mean ratio as “<125%” without point estimates or confidence intervals, and the ClinicalTrials.gov record lists no posted results.

Source: [ClinicalTrials.gov NCT06529796](https://clinicaltrials.gov/study/NCT06529796); [Hosey et al. (2026)](https://www.ajkd.org/article/S0272-6386%2826%2900494-4/pdf)

<a id="topic-3.1.7.9-2"></a>

###### No results posted in the registry record

> “No Results Posted”

Source: [ClinicalTrials.gov NCT06529796](https://clinicaltrials.gov/study/NCT06529796)

<a id="heading-3.1.8"></a>

#### 3.1.8 VX22-147-010

<a id="heading-3.1.8.1"></a>

##### 3.1.8.1 Objective

<a id="topic-3.1.8.1-1"></a>

###### Purpose stated in the registry record

> “The purpose of the study is to evaluate the relative bioavailability (BA) and the effect of food on the pharmacokinetics (PK), and the safety and tolerability of VX-147 test tablet formulation.”

Source: [ClinicalTrials.gov NCT05955872](https://clinicaltrials.gov/study/NCT05955872)

<a id="heading-3.1.8.2"></a>

##### 3.1.8.2 Location and Study Date

<a id="topic-3.1.8.2-1"></a>

###### Study dates and status in the registry record

| Field | Registry entry |
| --- | --- |
| Recruitment status | “Completed” |
| Study start (actual) | “2023-07-19” |
| Primary completion (actual) | “2023-09-02” |
| Study completion (actual) | “2023-09-02” |
| First posted | “2023-07-21” |
| Last update posted | “2023-09-13” |
| Other study ID numbers | “VX22-147-010” |

Source: [ClinicalTrials.gov NCT05955872](https://clinicaltrials.gov/study/NCT05955872)

<a id="topic-3.1.8.2-2"></a>

###### Study location in the registry record

> “This study has 1 location”
> “Salt Lake City, Utah, United States, 84124”

Source: [ClinicalTrials.gov NCT05955872](https://clinicaltrials.gov/study/NCT05955872)

<a id="heading-3.1.8.3"></a>

##### 3.1.8.3 Study Design

<a id="topic-3.1.8.3-1"></a>

###### Phase 1, open-label, randomized crossover design

> “A Phase 1, Open Label, Randomized, Crossover Study Evaluating the Relative Bioavailability and Food Effect of a VX-147 Test Tablet Formulation Compared to a Reference Tablet Formulation in Healthy Adult Subjects”

Source: [ClinicalTrials.gov NCT05955872](https://clinicaltrials.gov/study/NCT05955872)

<a id="topic-3.1.8.3-2"></a>

###### Design details in the registry record

| Field | Registry entry |
| --- | --- |
| Study type | “Interventional” |
| Phase | “Phase 1” |
| Primary purpose | “Treatment” |
| Allocation | “Randomized” |
| Interventional model | “Crossover Assignment” |
| Masking | “None (Open Label)” |

Source: [ClinicalTrials.gov NCT05955872](https://clinicaltrials.gov/study/NCT05955872)

<a id="heading-3.1.8.4"></a>

##### 3.1.8.4 Eligibility Criteria

<a id="topic-3.1.8.4-1"></a>

###### Key criteria in the registry record

> “Body mass index (BMI) of 18.0 to 32.0 kilogram per square meter (kg/m^2), inclusive”
> “A total body weight greater than 50 kg”
> “History of febrile illness or other acute illness that has not fully resolved within 14 days before the first dose of study drug”
> “Any condition possibly affecting drug absorption”

Source: [ClinicalTrials.gov NCT05955872](https://clinicaltrials.gov/study/NCT05955872)

<a id="topic-3.1.8.4-2"></a>

###### Age range and healthy volunteers

| Field | Registry entry |
| --- | --- |
| Ages eligible | “18 Years to 55 Years” |
| Sexes eligible | “All” |
| Accepts healthy volunteers | “Yes” |

Source: [ClinicalTrials.gov NCT05955872](https://clinicaltrials.gov/study/NCT05955872)

<a id="heading-3.1.8.5"></a>

##### 3.1.8.5 Treatment

<a id="topic-3.1.8.5-1"></a>

###### Three treatment sequences of test and reference tablets, fed and fasted

> “Participants will receive VX-147 reference tablet under fasted condition in Treatment Period 1, then VX-147 test tablet under fed condition in Treatment Period 2, and VX-147 test tablet under fasted condition in Treatment Period 3. A washout period of 5 days will be maintained between 3 treatment periods.”
> “Participants will receive VX-147 test tablet under fed condition in Treatment Period 1, then VX-147 test tablet under fasted condition in Treatment Period 2, and VX-147 reference tablet under fasted condition in Treatment Period 3. A washout period of 5 days will be maintained between 3 treatment periods.”
> “Participants will receive VX-147 test tablet under fasted condition in Treatment Period 1, then VX-147 reference tablet under fasted condition in Treatment Period 2, and VX-147 test tablet under fed condition in Treatment Period 3. A washout period of 5 days will be maintained between 3 treatment periods.”
> “Tablets for oral administration.”

Source: [ClinicalTrials.gov NCT05955872](https://clinicaltrials.gov/study/NCT05955872)

<a id="heading-3.1.8.6"></a>

##### 3.1.8.6 Study Outcomes

<a id="heading-3.1.8.6.1"></a>

###### 3.1.8.6.1 Rationale for Using Relative Bioavailability and Food Effect on Cmax and AUC0-inf as the Primary Endpoints

<a id="topic-3.1.8.6.1-1"></a>

###### Registered primary and secondary outcomes

| Outcome | Measure | Time frame |
| --- | --- | --- |
| Primary | “Maximum Observed Plasma Concentration (Cmax) of VX-147 Test Compared to VX-147 Reference” | “From Day 1 up to Day 16” |
| Primary | “Area Under the Concentration Versus Time Curve From the Time of Dosing Extrapolated to Infinity (AUC0-inf) of VX-147 Test Compared to VX-147 Reference” | “From Day 1 up to Day 16” |
| Primary | “Cmax of VX-147 Test Compared Under Fed Versus Fasted State” | “From Day 1 up to Day 16” |
| Primary | “AUC(0-inf) of VX-147 Test Compared Under Fed Versus Fasted State” | “From Day 1 up to Day 16” |
| Secondary | “Safety and Tolerability as Assessed by Number of Participants with Adverse Events (AEs) and Serious AEs” | “From Day -1 up to Day 27” |

Source: [ClinicalTrials.gov NCT05955872](https://clinicaltrials.gov/study/NCT05955872)

<a id="heading-3.1.8.7"></a>

##### 3.1.8.7 Statistical Analysis Description

<a id="heading-3.1.8.7.1"></a>

###### 3.1.8.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.8.7.1-1"></a>

###### Enrollment in the registry record

| Field | Registry entry |
| --- | --- |
| Enrollment (actual) | “21” |

Source: [ClinicalTrials.gov NCT05955872](https://clinicaltrials.gov/study/NCT05955872)

<a id="heading-3.1.8.7.2"></a>

###### 3.1.8.7.2 Description of Analysis Sets

No evidence found.

<a id="heading-3.1.8.8"></a>

##### 3.1.8.8 Results

<a id="heading-3.1.8.8.1"></a>

###### 3.1.8.8.1 Participant Disposition

No evidence found.

<a id="heading-3.1.8.8.2"></a>

###### 3.1.8.8.2 Baseline Characteristics

No evidence found.

<a id="heading-3.1.8.8.3"></a>

###### 3.1.8.8.3 Efficacy Results

No evidence found.

<a id="heading-3.1.8.8.4"></a>

###### 3.1.8.8.4 Health-related Quality of Life and Patient-reported Outcomes

Not applicable.

<a id="heading-3.1.8.8.5"></a>

###### 3.1.8.8.5 Safety Results

No evidence found.

<a id="heading-3.1.8.9"></a>

##### 3.1.8.9 Study Limitations

<a id="topic-3.1.8.9-1"></a>

###### Summary: study limitations

VX22-147-010 enrolled 21 healthy adults aged 18 to 55 years at one United States site and compared a test tablet with a reference tablet, and the test tablet fed with fasted, in a three-period crossover with 5-day washouts. The study was completed on 2023-09-02, but the ClinicalTrials.gov record lists no posted results, and no publication or congress abstract reporting its results was identified. The registry record does not state the dose or the composition of the test meal.

Source: [ClinicalTrials.gov NCT05955872](https://clinicaltrials.gov/study/NCT05955872)

<a id="topic-3.1.8.9-2"></a>

###### No results posted in the registry record

> “No Results Posted”

Source: [ClinicalTrials.gov NCT05955872](https://clinicaltrials.gov/study/NCT05955872)

## Related pages
- [Inaxaplin (VX-147): APOL1-mediated kidney disease](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Terms and abbreviations](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/terms-and-abbreviations.md)
- [Inaxaplin (VX-147): APOL1-mediated kidney disease](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/executive-summary) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/executive-summary.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Product information and disease description](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/product-information-and-disease-description.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Economic information and modeling report](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/economics) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/economics.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: References](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/references) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/references.md)
